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1  INTRODUCTION 
Market relations in the period of 2014 - 2015 years have been characterized by enhanced 
instability, the presence of uncertainty of the environment, increased competition between 
manufacturers. Sanctions against Russia, the import substitution program, the state program 
for the replacement of imported goods, budget deficit and reduction of purchasing power 
forcing manufacturers rapidly satisfy demand of different groups of consumers and maintain 
competitiveness. Under these conditions enterprises need to minimize the production costs 
and the costs of promotion. Reduced investment rating of Russia brought a decrease in 
financial and intellectual investment. In this regard, before the enterprises sharply rise 
competitiveness problems and search for additional sources of maintaining economic 
stability. One of the most important strategic management tools, which help enterprises 
adapt to the changing market environment, is optimization of the product portfolio. 
Optimally matched portfolio affects on sales, enables to control marginal income and net 
profit shares in the company's revenue. Product Portfolio Management allows operatively 
make changes to its structure, to maintain a competitive position in the consumer and 
commodity markets, to optimize capacity utilization and reducing costs. As a result, it 
provides economic stability of the enterprise. The product portfolio has to be balanced. 
Theoretical aspects of the portfolio formation are developing by economists since the 
second half of the twentieth century. General principles of its analysis and management laid 
by scientist all over the world: I. Ansoff, D.V. Arutyunova, K. Bowman, A. Vaismana, L.P.  
Vladimirova, P. Drucker, G. Inozemtsev, A.P. Gradova, F. Kotler, M. Porter, B.D. 
Henderson, J. Trout, AA Thompson, K. Stern and others. Literature analysis shows that, 
despite the great interest in this subject there are no common view on the definition of the 
portfolio, no comprehensive approach to its formation and analysis. However manufactures 
use simplified or approximate techniques of product portfolio management. At the same 
time, ever-changing markets require modifications of existing methods and models. 
Today many small and medium companies in Russia make decisions based on intuitive 
assumptions and experience, without paying due attention to the specialized methods of 
management. With the expansion of the product portfolio, the question of its effective 
formation and management becomes very important.  
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The aim of the thesis is to develop theoretical and methodological principles as well as 
practical advices on managing the enterprise portfolio, using the matrix method.  
The main subject of research is the process of product portfolio management, aimed at 
increasing competitiveness and economic efficiency of enterprises.  
The object of the study and the customer is a pharmaceutical company ZAO «Severnaya 
Zvezda».  
Theoretical and methodological basis of the thesis are the results of research 
scientists in product portfolio management. The study used scientific methods: comparison, 
analysis, synthesis, concretization, abstraction and other based on the theory of knowledge 
and the principles of dialectic methods of systematic methodology, methods of economic 
analysis, statistics, expert evaluations. In this work were used matrix methods of portfolio 
analysis. 
The regulatory basis are the law of the Russian Federation, decisions and orders of the 
government line ministries (Ministry of Health, Ministry of Industry and Trade of the 
Russian Federation), the data of the state register of medicines of the Russian Federation, 
regulations, state standards, guidelines. 
The empirical basis are the internal documentation of the company ZAO «Severnaya 
Zvezda», proceedings of the international and russian scientific-practical conferences, 
publications in the press, the study of specialized marketing companies (DSM – groups, 
Pharmexpert and others), the data of medical reference books and studies of author. 
The scientific novelty of the research are follows: 
 formulated general and specific principles of decision-making for product portfolio 
management  
 offered an algorithm of matrix methods of portfolio analysis for specific enterprise; 
 developed a technique of organizing the process of product portfolio management 
for pharmaceutical industry. 
The practical significance of the work lies in the fact that the theoretical results are brought 
to the level of specific practical recommendations, and may be used for further research, 
theoretical studies and practical activities of enterprises. In the work was identified the 
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potential development of the product portfolio of the pharmaceutical manufacture. The 
portfolio has been divided into groups. Were used additional features of the product to 
maintain its competitiveness and reduce the costs of promotion.  
The recommendations of product portfolio management accounted and used on an 
enterprise ZAO "Severnaya Zvezda". 
The new algorithm of portfolio analysis for pharmaceutical companies will be based on 
integration of matrix method with international classifications of disease and anatomical 
therapeutic chemical classification system. Also was proposed a classification of products, 
according to which the portfolio consists of three product levels. The portfolio consisting of 
first level products is the simplest for analysis. The portfolio, consisting of third level 
products, is the most sophisticated for analysis and requires the application of several 
analysis matrices in order to take the objective strategy. For the purpose of most effective 
distribution of investment resources between products of different levels it is necessary to 
additionally evaluate the feasibility, potential risks and strategic development prospects for 
each of it. 
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2  PORTFOLIO ANALYSIS AND ITS ROLE IN THE STRATEGIC MANAGEMENT 
Nowadays enterprises are worried by the decreasing share of the marginal income, as well as 
of the net profit share in proceeds. This situation is stipulated by different factors, but there 
are common reasons, namely, “bad” product portfolio (Kulinich, 2013).  
In modern competition conditions the market is determined by the product range and the 
enterprise’s task is to satisfy the demand, providing more quality and efficiency products and 
services than competitors. The level of real and potential profit, the stability of competitive 
positions at prospective markets, the economic stability and the possibility for a company 
development depends on the structure of the product portfolio. This requires carry out the 
planning, creation and management of product portfolio. The enterprise should timely 
provide a set of goods that fit the profile of its production operations and satisfying 
customers as much as possible. 
The competitive strategy is built on the product portfolio management. The product 
portfolio is a list of kinds of products, manufactured by the enterprise. All products undergo 
a certain life cycle in their development, lose its actuality, and become obsolete. The 
portfolio optimization should be carried out regularly, basing on most modern methods of 
evaluation and prospective of market products. The company portfolio should be balanced, 
i.e. shall provide the right combination of subdivisions or products, needing capital for its 
growth, with economical entities, disposing of some capital surplus. The portfolio analysis 
can keep balancing such key business factors as risk, money inflow, renovation and regres-
sion (Volkova, 2013). 
Basic principles of formation optimal portfolio (Arutyunova, 2010): 
 diversification of risk; 
 diversification of the stages of the life cycle of objects; 
 diversification of investment objects and «donors». 
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2.1  The definition of portfolio analysis 
The portfolio analysis is a key strategic business component (SBC). This is a method, by 
means of which strategic business units (SBU) of a company are analyzed cumulatively, 
allowing revealing key fields of activities, determining the company mission (Vixancky, 
1998).  
The portfolio analysis gives a clear impression on the field of company’s activities, as well as 
on the mutual relation of business parts, representing it as integral whole. It helps to evaluate 
economical activities, where funds are invested, and investments to inefficient projects are 
curtailed or terminated. The portfolio analysis makes it possible to evaluate the relative 
attractiveness of markets, as well as the competitive ability of each of them. It allows 
obtaining typical strategic recommendations and is an important stage of marketing strategy 
development (Tekutjev, 2012) (Kochugueva 2012).  
The essence of the portfolio analysis - the company is considered as integrity of strategic 
business units. The purpose of the portfolio analysis is to coordinate strategies and to use 
existing investment resources from the point of view of achievement of stable company 
position in whole, as well as the growth of financial results (Ries, 2014).  
In order to distribute investment resources between strategic business units in a most 
effective way it is necessary to evaluate potential feasibility, risks and strategic prospects for 
the elaboration each of them. Generally, the portfolio analysis is built on the rule that the 
higher the potential of a business unit development (sales and profit growth) and the lower 
risks, the more profitable investment to such unit. Investment resources can be both 
external and internal (profit of other business units). Also it should be highlighted that 
analysis allows avoiding the “unifying” approach to the development of such business units 
while creating corporate strategies. The independent priorities and goals are specified for 
each business unit, meeting its position in the market, as well as the role in the portfolio 
(L.K Serga, 2012).  
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2.2  Six Steps of portfolio analysis 
According to Vixancky, one of the founders and leaders of the Russian School of 
Management, portfolio analysis is carried out in six steps. (1998) 
The first step is a choice of levels in the organization to analyze the portfolio. It is a 
prerequisite, since the firm cannot executes the analysis of only on the company's micro 
level.  
The second step - fixing units for analysis, called strategic business units (SEB), to use them 
for positioning on the matrices of product portfolio. SEB often differ from the production 
units. They may cover one or more goods that meet similar needs. Some companies are 
considering SEB as product-market segments.  
The third step - definition of the matrix analysis parameters in order to have clarity regarding 
the collection of necessary information, as well as to select the variables, which will be 
analyzed. For example, in the study of the sector attractiveness as these variables can serve 
the market size, the extent of protection against inflation, profitability, market growth rate, 
the extent of the prevalence in the world market.  
The fourth step - data collection and analysis is conducted on many ways, but priority is 
given four most important areas: 
 attractiveness of the industry from the perspective of having positive and negative 
aspects in the sector, the nature and extent of the risk, etc; 
 competitive position of firms in the industry, as well as the overall competitive posi-
tion of the company; 
 opportunities and threats of the enterprise; 
 resources and skills, considered from the point of presence at the company's capacity 
to compete in each of the industries. 
The fifth step - the construction and analysis of the product portfolio matrix, which should 
give an idea of its current state, on the basis of which it is possible to predict the future state 
of the matrix, and consequently the expected company's product portfolio.  
The sixth step - determining the desired product portfolio is carried according parameters 
which can best contribute to achieving company’s goals. 
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2.3  Matrix methods for analysis of the product portfolio 
The most common methods of portfolio analysis are matrices. Such analysis is not decision-
making tool. Matrix shows the status of product portfolio, which should be taken into 
account by management in decision-making. They are usually two-dimensional table, where 
the values of the axes laid considered factors (an important condition: among factors should 
not be a strict functional dependence). Quadrants formed by the intersection of border 
values of both factors. The given quadrant indicates the applicability to business units of 
standard strategic recommendations. 
The following are the most well-known methods of matrix analysis that were used to 
develop a model management of product portfolio for the ZAO Severnaya Zvezda. The 
choice of these matrices is explained with the fact that the client is not advanced user of 
such tools. Analysis of the portfolio must be full, but simple enough to implement, so the 
company will able to use it on their own, without continuous outsourcing or hiring an 
additional manager. 
2.3.1  BCG Growth-Share Matrix 
In 1960th Boston Consulting Group has developed BCG Matrix, which is an internal 
assessment of the products or services offered by the firm (Orcullo, 2007). It provides a 
basis for evaluation of the relative performance of the businesses in which an organization is 
operating and making the organization more competitive it also prescribes the preferred 
distribution of cash and other resources among these businesses (Griffin, 2008).  
The matrix consists of two axes: one showing market growth and the other showing market 
share. The resulting four quadrants form the categories by which an organization can classify 
its business units or products on the basis of their relative market shares and growth rates 
(Boston Matrix). Matrix classifies the types of business units into four categories as stars, 
question marks, cash cows and dogs (See Figure 1). Company must have range of products 
both with high growth potential (requiring investments of cash) and goods with low growth 
potential (delivering cash) to ensure long-term value creation. According to the matrix, in 
the product portfolio should be several cash cows, 1-2 stars, a few question marks, and the 
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minimum number of dogs. The advantages and disadvantages of using this method are 
shown in Table 1. 
 
Figure 1. The BCG Matrix  
Table 1. The advantages and disadvantages of the growth-share matrix 
Advantages: Disadvantages: 
 provides a framework for allocating re-
sources among different business units; 
 allows to compare many business units at a 
glance; 
 matrix are clear and easy to build; 
 model simplifies the complex process of 
decision-making; 
 link between market share and profitability 
is questionable since increasing market 
share can be very expensive; 
 approach may overemphasize high growth, 
since it ignores the potential of declining 
markets; 
 matrix considers market growth rate to be a 
given, but in practice the firm may be able 
to grow the market; 
 the growth rate of the market can not re-
flect: 
o attractiveness of the sector as a whole 
because there are many factors affecting it 
(entry barriers, macro and micro economic 
factors); 
o profitability of the industry, since high 
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Advantages: Disadvantages: 
growth rates and low barriers to entry may 
occur intense competition, which will make 
the industry not promising for the company; 
 the relative share of the market cannot talk 
about the competitiveness of goods, be-
cause it is result of past effort and ensure 
product leadership in the future; 
2.3.2  GE / McKinsey Matrix 
The General Electric\McKinsey Matrix - is method of assessing the competitive position of 
companies on the market or the product portfolio analysis of strategic business units 
(SBUs), where the choice of strategic decisions depends on the market share, profit margins, 
the price position of product quality, the efficiency of sales, and the success of the staff 
image. The scheme of the GE matrix is a quadrant formed by two axes, where the vertical 
axis - the industry attractiveness and the horizontal axis - is a competitive segment or 
business strength. Each of them is divided into three parts: low, medium and high 
(Kevorkov V., 2013). The strategic position of the business improved as it moves from right 
to left on the matrix from the bottom up. Each quadrant has its own strategy. The matrix is 
shown on Figure 2. The advantages and disadvantages are represented in Table 2. 
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Figure 2. The General Electric / McKinsey matrix 
The GE matrix General analysis is carried out on the parameters "strategic business area" 
and "competitive position" There is three areas of the strategic position (GE matrix): 
 Green - Area of "winners" - an area of high potential (three top-quadrants). This is a 
business that has the best or average compared to other factors of attractiveness of 
the market value and benefits of the company. 
 Orange - Average area or border (three middle quadrants). This is a business, which 
under certain conditions can either grow and turn into "winners" or shrink and be-
come "losers". Three diagonal quadrants have an average attractiveness. 
 Red - Area of “losers” - an area of low potential (three lower quadrants). These 
businesses that have at least one of the lower and do not possess any of the higher 
parameters plotted along the axes. 
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Table 2. The advantages and disadvantages of the GE / McKinsey matrix  
Advantages: Disadvantages: 
 used in the presence of a large number of 
individual strategic business units and prod-
uct lines; 
 can be used at all levels within the company. 
At the corporate level, the elements of the 
business portfolio can be analyzed using 
this matrix. At the level of the business 
units can be analyzed individual products. 
 increasing the dimension of the matrix up 
to 3x3 allowed not only to give a more de-
tailed classification of comparable types of 
business, but also consider the wider oppor-
tunities of strategic choice; 
 allows us to consider the dynamics of the 
second factor - the attractiveness of the 
strategic business areas; 
 the matrix is a convenient tool to prioritize 
investing in various types of business and 
for the reallocation of resources; 
 there is a risk that the focus on growth 
businesses related to the “winners”, one day 
will enter to overloading area of investment 
resources, which will cease to give the de-
sired effect; 
 the short term is very difficult to assess the 
correctness of investments in businesses re-
lated to the winners, since the effect can oc-
cur much later; 
 assess of market attractiveness is based on 
the assumption that it necessarily reflects 
the average profit potential in the long term 
for all industry members; 
 matrix strategies are only recommendations 
and serve as a reference for further in-depth 
analysis and cannot be regarded as a man-
agement decision; 
 a breakdown of the matrix axes is contro-
versial: 
o it does not varies with a change of eval-
uated factors; 
o it lost rational core comprehensiveness, 
than only a few estimates made up the one 
that determines the coordinates of the posi-
tion of business on the corresponding axis; 
While the GE business screen represents an improvement over the simpler BCG growth-
share matrix, it still presents a somewhat limited view by not considering interactions among 
the business units and by neglecting to address the core competencies leading to value 
creation. Rather than serving as the primary tool for resource allocation, portfolio matrices 
are better suited to displaying a quick synopsis of the strategic business units. (GE/ 
McKinsey Matrix).  
2.3.3  Ansoff Matrix 
Igor Ansoff presented a matrix that focused on the firm's present and potential products 
and markets (customers) to portray alternative corporate growth strategies. By considering 
ways to grow via existing products and new products, and in existing markets and new 
markets, there are four possible product-market combinations (Ansoff Matrix). Ansoff's 
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matrix is shown below: (See Figure 3). The advantages and disadvantages are represented in 
Table 3. 
 
Figure 3. The I. Ansoff matrix 
Ansoff's matrix provides four different growth strategies (Ansoff Matrix): 
 Market Penetration - the firm seeks to achieve growth with existing products in their 
current market segments, aiming to increase its market share. 
 Market Development - the firm seeks growth by targeting its existing products to 
new market segments. 
 Product Development - the firms develops new products targeted to its existing 
market segments. 
 Diversification - the firm grows by diversifying into new businesses by developing 
new products for new markets. 
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Table 3. The advantages and disadvantages of the I. Ansoff matrix 
Advantages: Disadvantages: 
 matrix is a simply graphical toll that allows a 
business or individual to weigh up a com-
plex situation or decision; 
 can be used to explore the different direc-
tions for strategic growth; 
 four strategic options can be generically ap-
plied to any industry; 
  matrix is highly simplistic and does not fac-
tor in the external environment, especially 
within a business context; 
 each strategy carries a certain amount of 
risk and involves investments; 
 cannot be used alone to justify the decision; 
2.3.4  Arthur D. Little Matrix 
The ADL portfolio management approach uses the dimensions of environmental 
assessment through competitive position and business strength assessment through industry 
maturity category. Its application is particularly suited to smaller industrial companies and 
for strategic business units of large companies (Little, 1980). Each of these dimensions can 
be dividing into the following categories to better analyze a company and accordingly 
determine the future strategic actions. Competitive position can be either of the following 
(ADL Matrix): 
 Dominant - the position of a company falls into this category if it is a clear market 
leader or has a monopoly position.  
 Strong - the company might not be a monopoly but definitely has a strong presence 
and loyal customers. 
 Favorable - companies with favorable competitive position usually operate in frag-
mented markets and no single one controls all market share. 
 Tenable - each company caters to a niche segment defined by a product variety or 
segmented demographically. 
 Weak - the company financials are too weak to gain a strong hold in the market and 
is expected to die out within a short span of time.  
According on where SBU lies on the ADL grid, a suitable kit of strategies should be chosen 
by it to gain competitive positions, greater market share and move to higher stages of life 
cycle. The matrix is shown below: (See Figure 4). The advantages and disadvantages are 
represented in Table 4. 
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Figure 4. The ADL matrix 
Table 4. The advantages and disadvantages of the ADL matrix 
Advantages: Disadvantages: 
 Transparency; 
 Flexibility in assessing the attractiveness of 
the industry; 
 Possibility of balancing a portfolio of pro-
duction; 
 Better identification of competition, suppli-
ers, customers, potential substitutes; 
 Allows to extract the strengths of the prod-
 Excessive empiricism and subjectivity in the 
application of the criteria for designation of 
its main dimensions; 
 ADL is limited to only those strategies that 
are not trying to change the life cycle, so 
following the model makes it impossible to 
develop a strategy that takes into account 
the situation of such a change. 
 Theoretical prerequisite of matrix approach 
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Advantages: Disadvantages: 
uct portfolio; 
 ADL approach is especially useful for high-
tech industries, where product life cycle is 
very short and where business cannot 
achieve their goals if time does not apply 
the necessary strategy; 
 Can be applied to the fragmented indus-
tries, holding a small competitive advantage 
but with a large number of ways of obtain-
ing it (provides multiple ways of differentia-
tion). The ADL matrix has a high degree of 
adaptability to situations of a qualitative na-
ture 
is a condition of fragmentary competition in 
the industry in its infancy, which does not 
always correspond to practice. 
 The length of the life cycle might be influ-
ence by the competitors of the firm. 
 Effective planning requires a definite time 
frame; a rapid change in the industry life cy-
cle can make a chosen course of action ob-
solete and harm the company’s competitive 
position.  
2.3.5  АBС+ZУX  
ABC analysis is a common method of studying the range by which can determine the 
contribution of each product in the store turnover and profit, to distribute products by 
categories for efficient portfolio management (Combined ABC and XYZ analysis). The 
advantages and disadvantages are represented in Table 5.  
Table 5. The advantages and disadvantages of the ABC analysis 
Advantages: Disadvantages: 
 rationalization of the range management 
makes clear the importance of goods to dis-
tribute effort store manager, 
 quick results and rapid application of ad-
ministrative decisions; 
 •if done regularly over the previous period 
makes it possible to track the stages of the 
life cycle of products. 
 • amount of data needed for analytics dur-
ing a certain period: the base on checks, 
sales or other retail data; 
 if there are any unforeseen situations on 
market (sharp inflation, political unrest, 
etc.), these ABC analysis may be inaccurate. 
XYZ-analysis determines the stability of product sales for the period. The results allow to 
divide the products into categories and to allocate a place for them in the warehouse, 
inventory levels and delivery organization (Combined ABC and XYZ analysis). The 
advantages and disadvantages are represented in Table 6. 
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Table 6. The advantages and disadvantages of the ZYX analysis 
Advantages: Disadvantages: 
  Data management for a variety of goods 
and inventory management, organization of 
work with suppliers; 
  setting of different delivery options for dif-
ferent categories of products; 
  Use analysis to predict the stability of de-
mand; 
  determination of the problem with unsta-
ble stores sales; 
 definition of commodity holes, the correc-
tion of the supply chain of goods. 
  need, as well as for ABC, for stability indi-
cators, without concussions the market; 
  Necessary data for several years for a full 
analysis; 
  difficult to work with seasonal products; 
  cannot be used on products with short life 
cycles. 
 
The combination of ABC and XYZ analysis reveals the absolute leaders (group AH) and 
outsiders (CZ). If ABC analysis allows estimating the contribution of each product in the 
sales structure, the XYZ-analysis to evaluate jumps marketing and instability. The results of 
this analysis can be used to optimize the range, evaluations of profitability of product 
groups, evaluation of logistics, consumer ratings wholesale company (ABC and XYZ 
analysis). Matrix is shown in the Figure 5. 
 
Figure 5. The ABC - ZYX matrix 
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Using a combined analysis provides a number of additional advantages (Combined ABC and 
XYZ analysis) (ABC+XYZ):: 
 identification of goods with stable sales, significant turnover for the store, and loss 
of goods; 
 increasing the share of profitable products without violating the principles of the as-
sortment policy; 
 determining the causes that affect the amount and location of the goods stored in 
the warehouse; 
 redistribution of effort management staff range and inventory. 
The matrices can be used to analyze a single product or entire industry. There are no perfect 
goods and no perfect methods of analysis. Each product has specific properties. Every 
analysis has advantages and disadvantages. For obtaining an objective analysis of the product 
portfolio it is necessary to use combinations of matrices. The data allows developing a 
strategy for each product and management model of product portfolio.  
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3  IMPROVEMENT OF THE PRODUCT PORTFOLIO MANAGEMENT MODEL 
The model of management - is not an invention, it is an evolution. 
 (Frederick Taylor) 
The evolution of management thought is most clearly reflected in the management models 
that scientists and specialists develop and then implement in practice with a view to solve 
the problems. The models themselves are not frozen and can be transformed and converted 
in accordance with changes in the market. The main task of the manager is to properly 
integrate all the major trends and adopt the most effective model. 
Under the "management model" should be understood set of ideas about how should look 
the management system, how it affects the control object, how adapts to changes in the 
external environment. This enables company to achieve its goals, develop sustainably and 
ensure its viability (The concept, features and functions of management, 2015). The model 
includes the basic principles of management, strategic vision, targets, values, structure and 
coordination of its elements, organizational culture, analysis and control, driving forces of 
development and motivational policies. 
In accordance with established practice, a model which the manager seems perfect or the 
most appropriate can be (Gaponenko, 2003): 
 ready-made model, bearing in mind that the global experience of practical manage-
ment gave a considerable number of methods, which in due time and under certain 
conditions gave a positive result; 
 build a model of the most effective parts and pieces of various management models, 
using the assembly method; 
 choose a basic model of management that meets the requirements, exclude un-
wanted elements from it, elaborate and build new elements which meet the specific 
characteristics of a managed object and conditions of its functioning; 
 create and launch an entirely new model based on a new paradigm, able grasp the 
emerging changes in the external environment, which will become dominant in the 
future. 
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The optimal use of the available production and financial resources for maximum 
compliance of products range demands of consumers is a condition for enterprises’ 
development. The main task of the portfolio management is the optimization of financial 
results of enterprises’ activities. 
Features of the Russian market influence on the formation and management of product 
portfolio. The following peculiarities can be distinguished: 
 Russian manufacturers are not “trendsetters” for the majority of products, but are 
manufacturing products “looking like” imported analogues; 
 one group products, having different trade names, have got different competitive 
positions in the market (the difference in price and the life cycle of a branded prod-
uct can differ from the analogue in several times); 
 enterprises lack internal resources for the timely and adequate reaction to market 
changes; 
 certain market trends or restrictions (state regulation etc.) in the market segments. 
Volumes of production costs depend on the product range selection. The nomenclature 
curtails by 50% increases the production capacity by 30%, reduces costs by 17% and 
decreases the breakeven point. When the product range extends by 50%, costs are increased 
by 20–35% per production unit. The excess product range reduction causes the drastic 
decrease of sales due to the lack of products, being of consumers’ demand (Kevorkov V., 
Product Portfolio Management of the Company, 2013).  
Solving the problem of product portfolio management, the company solves the problems of 
costs, load of production capacities and sales, and profits. 
3.1  Development of the offers for detailing product classification  
The product portfolio is the integrity of total products (groups of products, kinds and 
species of products), which can be manufactured within frames of organizational, economic 
and technologic conditions of such production (manufacturing with the same park 
equipment). Practically, the portfolio is integrity of products, having different profitability 
level and undergoing different life cycle stages, and, as a consequence, having different 
market prospects. Due to the different life cycle continuity the portfolio composition is 
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variable, what is stipulated by the withdrawal of old products and mastering of new ones 
(portfolio rotation). Its composition and structure should meet the integrity of different 
goals of the enterprise planning.  
The product portfolio management is a sophisticated process, meaning the selection of the 
optimal solution, while taking into consideration all possible optimization criteria and 
restrictions, taking place in existing and possible conditions while implementing different 
development alternatives. Depending on the kind of tasks, for which achievement of the 
portfolio structure is oriented, as well as on the time period, within which it is planned to 
achieve target indices, different types of products’ classification inside the portfolio can be 
applied. Formation the product portfolio was based on the fact, that for each product, 
consumers’ needs are to be determined, e.g. the total of features, describing certain product 
consumers in detail. Consumers should treat the product equally from the point of view of 
its discovered merits, apply it in a similar way and to react likewise to instruments of 
marketing activities (price, advertising etc.), to demonstrate the likely behaviour, as well as 
the loyalty to the product. In this case, depending on their value system, consumers and, 
accordingly, products, will be grouped in separate groups. It proposed to introduce the 
concept of "product level" and to create the products’ classification by levels. For the 
product portfolio it is necessary to determine the hierarchy of analysis levels. It offered to 
establish the products’ hierarchy. For classification purposes used such notion as “strategic 
business unit (SBU)”. 
The first level product is a strategic business unit (SBU) – an organizational unit, 
responsible for the development of the company strategy in the target market. It has market 
purpose, an independent development trend or a company subdivision, a mission, its own 
products’ lines, specific competitors and its own sales markets. For example the first level 
product can be considered as business trend or a group of products. 
The second level product is a strategic business unit (SBU) – an organizational unit, 
responsible for the development of the strategy in the product line. It has own market 
target, an independent development trend, specific competitors and own sales markets. For 
example the second level product can be considered as product line inside a group of 
products.  
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The third level product is a strategic business unit (SBU) – an organizational unit, 
responsible for the development of the strategy for one or several products or kinds of 
goods, satisfying alike needs, occupying a certain position in the market segment and having 
common production and promotion peculiarities. The third level product is a kind of 
product, which can comprise different kinds of package, sorting and dosage. Typically, such 
product has got a trade mark (brand). Several third level products make a second level 
product. 
Provided peculiarities of such classification for each level product offered to use different 
strategies (short term or long term), monitoring periods, as well as the financial evaluation of 
changes. In such case the portfolio analysis is used for the analysis of the relevant level 
product. Strategic business units are being analyzed in total, provided optimization criteria 
and restrictions allow revealing key operations. The application of such a classification 
allows simplifying the product portfolio analysis at the expense of reduction of the quantity 
of analyzed products.  
Most companies having different product range, financial capacities, working in different 
markets. They use product portfolio analysis methods to form the strategy, oriented for 
long-term goals. The main shortage of such analysis is that the current status data cannot 
always be extrapolated to the future, or it can cause an error. The application of levels 
classification allows obtaining more authentic data.  
Each enterprise has got its own sales’ profile. There are product portfolios where 2 products 
are dominating. There are also a few with 5-6 denominations. The analysis is based on 
structuring the product portfolio by three levels: 
 1st level – a group of products. At this level the product portfolio is divided into 
groups of products with same designation/trend, having its own market. Market 
changes are being analyzed in whole, as well as selected segments. 
 2nd level – product line. These are substitute products from one group. At this level 
the products are consolidated into substitute products’ group. The company's prod-
uct groups are compared with groups in the market and analyze how they change.  
 3rd level – enterprise products. This level comprises all products, manufactured by 
the enterprise nowadays. Each product satisfies a certain need and it may have sev-
eral SKU (Stock Keeping Unit). 
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3.2  Development of the management algorithm 
As a rule, the product portfolio comprises three levels of products. Depending on target 
planning goals, products from three levels can be used, or products from different levels can 
be combined. Each level has got products, located at the certain lifecycle stage, and 
occupying leading, neutral or underperforming positions.  
The first level product (group of products) has got a life cycle, including conceiving, growth, 
and substitution of weak players, maturity and extinction. Usually it is compared with a 
branch life cycle. In relation to the branch life cycle products can be obsolete, new, 
innovation. At this level both internal and external environment factors are being analyzed. 
Among external factors the important role belongs to market attractiveness, its volume, 
dynamics, maturity, saturation, elasticity, peculiarity and market admission price, influences 
of state authorities, consumers’ preferences.  
It is recommended to analyze the enterprise with SWОT method before the analysis, in 
order to be aware of the current enterprise situation, its opportunities and threats. According 
to G. Inozemtsev (2005) for first level products the long term planning (2-5 years) is 
strategically important. For the analysis of such product it is recommended to use BCG 
matrix or to use the combination of SWОT-analysis and General Electric / McKinsey 
matrix. Having analyzed external macro- and micro-factors of the business environment, as 
well as of internal strong and weak point of the product level, will be reveal key figures of 
the success and main strategic problems, for which we need to preview mandatory changes 
and activities in the following action program (Inozemtsev, 2005). If it is necessary to extend 
the existing product portfolio to increase the sales, as well as the market share in the first 
level, it is possible to additionally do the PEST analysis. By results of analysis of the first 
level products strategic decisions can be made, as offered by the used matrix.  
The second level product is an independent trend of product lines’ development at one of 
target market segments. To analyze such products it is necessary to evaluate growth 
possibilities between existing products and existing markets, new products and existing 
markets, as well as new products and new markets. It is also necessary to analyze specific 
competitors, technological trends, substituting products and consumers’ demands. At this 
level both internal and external environmental factors are being analyzed. Among external 
factors the important role belongs to the breadth of the market, its maturity, saturation, 
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competitive environment, and consumers’ demands. Among internal factors the main role 
belongs to the innovative technological component. According to Inozemtsev (2005) for 
second level products it is important to use long-term strategies (2-5 years), as well as short 
term tactic solutions (1 year). In the analysis of product should be used Ansoff matrix. For 
more detailed strategy development recommends to use АDL matrix. It allows planning 
product or service strategy in conformity with the life cycle stage of the branch, as well as 
with the level of competitive ability of the company in the market. АDL matrix allows 
determining the long-term development vector for the company and the product.  
Having analyzed external macro- and micro-factors of the business environment, as well as 
internal strong and weak points of second level products, will be found out: 
 the level of the market penetration; 
 what are opportunities for the product development; 
 what are opportunities for extension of the product market share; 
 diversification opportunities.  
Based on the results of the analysis of the second level products it is possible to make 
strategic decisions, offered by used matrices.  
The third level products consist of all the product names, manufactured by the enterprise at 
the present time. The portfolio analysis of these products evaluates the actuality of company 
products, depending on the growth of production market and the occupied share. The third 
level product is considered from the point of view of its promotion in the market. The life 
cycle of product comprises its launch in the market, growth, maturity and extinction. Such 
conditions require long term and short term tactic solutions. For this purpose АDL matrix 
will be suitable. In the interest of more detailed analysis BCG matrixes are used or additional 
analysis of statistic data. In the analysis of the product range inside the third level, methods 
of assortment analysis can be applied: АBС, ZУX, АBС+ZУX. 
The algorithm of the model of the product portfolio analysis: 
 analysis of the enterprise product portfolio 
 differentiation of the product portfolio into three levels. Group of products (the first 
level product is considered as business trend or a group of products). Product line 
(the second level product is considered as product line inside a group of products). 
Kind of product (the third level product); 
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 collection and analysis of statistic data; 
 selection and building of the product matrix; 
 selection of product strategy; 
 confirmation of the selected strategy and additional research; 
 implementation of the selected strategy and determination of control periods 
The algorithm includes several levels of decision making: 
First level of decision making – making of the decision on the product’s prospective (group 
of products) includes: 
 evaluation of the market potential includes evaluation of the economic situation, 
analysis of the market volume, structure and dynamics, determination of financial 
channels and of its prospects, analysis of market development trends, determination 
of the market capacity; 
 evaluation of the product potential includes evaluation of the competitive environ-
ment, evaluation of development prospects of the competitive environment; 
Second level of the decision making – development of the marketing strategy for the 
product (product line) launch to the market. It consists of: 
 evaluation of the product potential includes description of the existing application 
practice, determination of purchases’ process, product positioning, determination of 
the optimal price. 
 determination of the consumption potential includes segmenting and targeting of 
target audiences, determination of optimal promotion channels. 
For the third level products the second level of decision making is applied. 
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3.3  Analysis of the optimization results of the product portfolio management model  
Matrix, described in the second chapter, can be used for the analysis of all products levels. In 
order to obtain unbiased analysis results for each product it is better to use two matrixes, as 
following items are of importance: market changes, product changes, competitive 
environment changes, change of the enterprise itself.  
For the optimization of the management strategy, applied for the third level product, it is 
recommended to analysis the first and second level products, comprising the third level 
product. In order to develop the analysis inside the third level product following product 
range analysis methods can be applied: АBС, ZУX, АBС+ZУX. Due to such algorithm of 
the portfolio analysis, select whole strategic trend, strategy of product lines development and 
product development strategy. 
The developed method was tested on the example of a pharmaceutical company. Using this 
algorithm must take into account characteristics of the product and the market.  
In the pharmaceutical market for the consumer does not matter taste, color and smell of the 
product. His choice is based on a doctor's recommendation. However, if the product is 
effective, then the сonsumer will come again.  
Next, consider the other factors influencing the formation of the portfolio. 
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4  THE PHARMACEUTICAL INDUSTRY IN RUSSIA 
The pharmaceutical market in times of crisis and sanctions is the most stable segment of the 
economy, as its quite strong social component. Traditionally, the pharmaceutical market is 
one the most profitable markets both in Russia and abroad. The Russian pharmaceutical 
market ranks second in volume terms after the foodstuff market and is one of the most 
dynamic and promising specialized markets. Being mostly domestically oriented, the 
pharmaceutical market is less sensitive to exchange rate fluctuations than export-oriented 
industries and is quite stable. Another factor that positively influences its development is 
that the demand for pharmaceutical products does not strongly depend on the business 
cycle phase (AstonConsulting, 2012). 
According to the State Statistics Committee in 2014 drugs took about 2, 0% in the basic 
structure of consumer spending in Russia, which is higher by 0.1% than in 2013. Thus, the 
Committee has slightly increased importance of drugs in consumer spending. Figure 6 
shows the general consumer price index and price indices for certain categories of goods and 
services. The general index of consumer prices in 2014 amounted to 11.4%. At the same 
time the largest price increase was observed for food (15.4%). Least of all prices increase for 
gasoline (8.9%) and non-food products (8.1%). 
 
Figure 6. The consumer price index in Russia (December 2014 to December 2013) 
27 
 
4.1  The specificity of the pharmaceutical industry in Russia 
The pharmaceuticals’ market is a part of consumer goods and services market; it has он 
имеет следующие особенности got certain peculiarities, influencing its organization 
considerably. It has the following peculiarities:  
 broad product range of pharmaceuticals; 
 long term cycle of pharmaceuticals’ development; 
 high research intensity; 
 huge variety of technological processes, kinds of equipment, raw and other materials, 
used for the manufacturing of pharmaceuticals; 
 often amendments, extensions and renewals of the manufactured production; 
 manufacturing generics; 
 demand dependence on epidemics, natural disasters and other emergency situations; 
 trend for world globalization. 
The world globalization trend is stipulated by certain factors. All people need to protect and 
reinforce their health, aiming to prolong the life period. In different countries the dynamics 
of disease incidence, pathological and physiological mechanisms of diseases are similar. The 
high cost of development and implementation of new pharmaceuticals, requires joint efforts. 
Scientists need to exchange innovative technologies, as well as results of scientific & 
research works. Pharmaceutical companies tend to merge in order to capture a larger market 
share. There are common international standards for the manufacturing (GLP, GСP, GMP), 
distribution and pharmaceutical practice (GDP, GPP), storage and transportation of 
pharmaceuticals (DSP). 
Pharmaceuticals market structure – this is a system of mutually related and interacting 
production subjects and objects, distribution and consumption of pharmaceuticals. 
Subjects of pharmaceutical market are management and regulation authorities, production, 
distributors and pharmacies, specialized information & analytic editions, agencies, consulting 
companies, professional public organizations and consumers. 
Consumers of pharmaceutical production – is a sophisticated sub-system of pharmaceutical 
market subjects, having different motivations for the consumption of pharmaceutical 
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products, different values for its purchase, different methods, designation and process of 
consumption. They are divided into following types: 
 prevention and treatment facilities; 
 wholesale and retail drugstore establishments, pharmaceutical companies; 
 final consumers, their family members, using products for personal or family con-
sumption; 
 intermediate consumers – health workers (physicians), administering the substance 
for the purpose of its use within the hospital or prescribing a medicine to be used by 
outpatients.  
The pharmaceutical market of final consumers is segmented by different methods and in 
conformity with different criteria. The most common are demographic criteria (sex, age, and 
family membership), geographic criteria (district, residential density), social & economic 
criteria (income level, education), psychological criteria (life style, personal characteristics). 
There are following types of consumer behavior: super-innovators (3%), followers, majority, 
super-conservatives – people speaking against any changes (11 – 15%). It is based on 
consumers’ division depending on purchases’ motivation, consumption intensiveness and 
attitude to production: For example: 
 tried to apply a pharmaceutical – single time, repeated, frequent user;  
 generic user (price is selection criteria); 
 user adherent to a certain pharmaceutical (the selection criteria is confidence). 
One of the most important factors for end-user segmentation for prescription drugs is the 
behaviour of the doctor when he prescribed the medication. The interaction of physicians, 
pharmacies and patients can be schematically presented on Figure 7 
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Figure 7. The interaction between physicians, pharmacies and patients     
Pharmaceutical market objects are pharmaceutical products (pharmaceuticals and health 
products), services, information, customer “tastes” (needs), production quality, technologies.  
The sales structure of the pharmaceutical market divided to commodity and consumer 
groups. The medicines on the market are divided into prescription (Rx) and non-
prescription (OTC) drugs. 
The modern Russian pharmaceutical market regulated by Federal law on circulation of 
medicines (2010). All authorized medicinal products included in the State register of 
medicines. The domestic manufacturers mainly produce generic medicines. The imported 
medicines take a significant market share. The advertising of Rx drugs in the media is 
banned (Law, 2006). The federal target program: “Development of Russian pharmaceutical 
industry for the period up to 2020 and future outlook” is aimed to support domestic 
producers. In conditions of crisis 2014 - 2015 an increase in sales in rubles and fall in 
packages. This is due to higher prices for imported medicines.  
4.2  Main segments of the pharmaceutical market 
The pharmaceutical market of Russia in the structure of sales can be divided into two main 
segments, which are divided into sub-segments. The structure is shown in Table 7. 
Final 
consumers 
Pharmacies 
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Table 7. Segmentation of the Russian pharmaceutical market 
 
The Vital drug list (VDL) contains essential medications that reduce mortality and morbidity 
within the population. VDL is a guarantee that the government will provide the most 
essential drugs to its citizens (i.e. sufficient supplies of drugs in pharmacies and medical 
facilities as well as affordable prices for all consumers) (AstonConsulting, 2012). 
Currently the Vital drug list contains 608 INNs including 67% that are manufactured 
domestically (State Register of medicines, 2015). 
The State register of medicines, the Vital drug list and other specialized directories take into 
account the classifications of medication. 
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4.3  Classifications of medication 
There are two classifications of goods used in the pharmaceutical market (State Register of 
medicines, 2015):  
 the Nosological Classification (ICD) indications of the pharmaceutical drug" (thera-
peutic effect); 
 the Anatomical Therapeutic Chemical (ATC) Classification System (pharmacological 
effect) 
Nosological classification, i.e. groups of diseases or indications for use of medicinal product, 
takes into account the medical practice. There is an International Classification of Diseases 
(ICD), which describes the 22 class of diseases (WorldHealthOrganization) (State Register of 
medicines, 2015). The classification is available on the World Health Organization website.  
Each class has its own subclasses of disease. For example, a Class IX: Diseases of the 
circulatory system includes heart disease (OCH, DCS, IHD and others), diseases 
characterized by high blood pressure and others. For example Class XI: Diseases of the 
digestive system has subclasses diseases of the oral cavity,  diseases of the esophagus, 
stomach and intestines, liver disease and others (WorldHealthOrganization). 
Some classes of diseases have similar causes, symptoms, conditions, as well as similar 
methods of diagnostics and laboratory analysis (blood, urine, etc.). For example, Class V: 
Mental and behavioural disorders and Class VI: Diseases of the nervous system. 
The same principle used for training and specialization of physicians: therapy, cardiology, 
neurology, gastroenterology, oncology, obstetrics and gynaecology and other infectious 
diseases. 
The market classification by pharmaceutical drug indices is based on a certain group of 
symptoms: (e.g. cold, headache) or on a certain disease treatment (e.g. gastritis). This kind of 
classification is oriented to the customer, as both the physician and the patient refer 
symptoms to a certain disease. The disadvantage of this classification is that it does not take 
peculiarities of medical practice into consideration. A physician can select drug from 
different pharmacological groups for the treatment of a same disease. 
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The classification of disease is referred to the first level of АТС classification, where 
medications are distributed by kinds of nosological or pharmacological groups. The market 
classification by pharmacological groups provides the data for pharmaceuticals’ sales by 
pharmacological groups. АTС classification is carried out by World Health Organization 
Centre (WHO) collaborating centre for drug statistics methodology in Oslo, Norway. 
Adopted by the Health Ministry of the Russia (State Registry of Pharmaceutical Drugs, 
Health Ministry of the Russia, Moscow, 2002) (State Register of medicines, 2015) (ATC 
classification). The main therapeutic classification group are presented (first classification 
level) in Table 8. 
Table 8. First level ATC-classification 
ATC groups of I level 
Code Content: 
A Alimentary tract and metabolism 
B Blood and blood forming organs 
C Cardiovascular system 
D Dermatologicals 
G Genito-urinary system and sex hormones 
H Systemic hormonal preparations, excluding sex hormones and insulins 
J Antiinfectives for systemic use 
L Antineoplastic and immunomodulating agents 
M Musculo-skeletal system 
N Nervous system 
P Antiparasitic products, insecticides and 
repellents 
R Respiratory system 
S Sensory organs 
V Various 
~ Medicaments, without ATC-group 
A Alimentary tract and metabolism 
B Blood and blood forming organs 
C Cardiovascular system 
D Dermatologicals 
G Genito-urinary system and sex hormones 
H Systemic hormonal preparations, excluding sex hormones and insulins 
These classifications are used by all subjects of the pharmaceutical market. The market is 
valued according to the number of packages (i.e. in units of consumption goods) and in 
terms of cost. It is also estimated by product names, groups (based on ICD and ATC), the 
segments (OTC and RX drugs), and so forth. The joint analysis of both indicators gives an 
idea on pharmaceutical market trends. 
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4.4  How new method of product portfolio analysis will work with pharmaceuticals 
classifications? 
During the development of a new method of portfolio analysis were used ATC and ICD 
classifications. Thus the portfolio will be altered in way, that all types of doctors and 
costumer will be able to use and to understand it. Application of both classifications 
demonstrated on the example of blood circulation diseases. (See Figure 8) 
 
Figure 8. How ICD and ATC work together on the example of cardiovascular  
diseases 
For example on the International Classification of Diseases IX Class - are diseases of the 
circulatory system which includes groups, including ischemic heart disease (first level 
product). Groups are divided into subgroups such as ischemic heart disease is divided onto 
acute myocardial and etc (second level products). Used for treatment 52 API (corresponding 
INN), including 783 drugs, including 120 trademarks (third level products). All these 
medicaments divided by ATC classification. In the ATC classification exist pharmacological 
group, which includes drugs for heart diseases treatment that are actually divided into 
subgroups. Thus, when forming the first level product use ICD. When forming the second 
level product use ATC. When forming the third level product use INN - The international 
non-proprietary name.  
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Features of market segments, customers, and classifications of medications should be 
considered in the formation of a pharmaceutical company's product portfolio. Matrix 
methods can be applied to the analysis of specific products (third level product) and/or 
pharmacological groups (second level product) and/or groups of diseases (thirst level 
product). For example, such diseases as whooping cough and poliomyelitis are gone and and 
significantly decreased the market share of the vaccines. They moved into the category of 
dogs. At the same time has increased the market share occupied by immunological drugs. 
Now they are "cows" in the portfolios of pharmaceutical companies. Among the 
pharmacological groups appeared new group - statins (to lower cholesterol). They actively 
take market share of cardio. Innovative companies to optimize the portfolio work only with 
drugs for the treatment of one group of diseases (oncology) or one pharmacological group 
(antibiotics). Generic companies are trying to work with several groups of drugs. 
Analysis of the current situation on the Russian market is presented in Appendix1.  
The volume of Russian pharmaceutical market compared to other countries is presented in 
Appendix 2. 
4.5  Forecast of the Russian pharmaceutical market 
The Russian pharmaceutical market had a positive trend in 2015. 
Forecasts of the Russian pharmaceutical market development are quite positive. The market 
grew by 15% in rubles and equal to 1.3 trillion rubles (DSM Group). Forecasts of market 
growth are shown on Figure 9. 
Despite the positive growth forecasts for the Russian pharmaceutical market, experts believe 
that the crisis in Russia has just begun. According to Sergei Davydov, a business consultant 
and main partner of Management Centre Europe (Brussels), the factors that led to the crisis, 
has not yet disappeared. These factors are including (Davydov, 2015): 
 Internal factor:  
o inefficient oil and gas dependent economy; 
o labour productivity remained at the same level as many years ago, 25% of the 
US level, and wages rose more than 10 times; 
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o oil and gas revenues constitute about 50% of the income of the federal 
budget; 
o low investment attractiveness (in 2015, the international rating agency Stan-
dard & Poor's downgraded the credit rating of Russia to the level «BB +»); 
 External factor - sanctions. 
Forecasts by Russian Association of Pharmaceutical Marketing (2015): 
 fall of the market in packages and in the currency value; 
 reducing the level of margin and overall profitability of the majority of participants; 
 restriction on the price increases according to the level of the rubles fall to the sharp 
decline of purchasing power of the state and the population; 
 potential difficulties in the supply drugs from the VDL list because of fixing prices in 
rubbles (which means that their cost will be higher than the sale price); 
 the relative benefits for local producers. 
 
All these factors need to be considered in the management of product portfolio. 
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Figure 9. Forecast of the capacity and size of the pharmacological market in prices of final consumption in bln rub. and bln USD (Berezin, 2014) 
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5  CASE STUDY: ANALYSIS OF THE ZAO «SEVERNAYA ZVEZDA» PRODUCT 
PORTFOLIO  
ZAO ”Severnaya Zvezda” is dynamically developing pharmaceutical company. It exists in 
Russian market for more than 19 years. This is a modern manufacturing facility of ready-
made pharmaceutical products equipped in accordance with GMP international standards 
(See Appendix 3). The enterprise carries out its activities on the basis of License of the 
Federal Service for Supervision in the Field of Health Care and Social Development No. 
00003-ЛС-П dated 14.02.2014 "For Carrying Out Drug Manufacturing Activities" (See 
Appendix 4).  
Purpose of the enterprise is to provide high quality, appropriately priced products to the 
people, ensuring high profitability and competitiveness of the manufactured finished dosage 
forms (tablets and capsules). All manufactured drugs are divided into the following classes 
regarding their pharmacological activity:  
 cardiovascular drugs,  
 neurological drugs, 
 gastrointestinal drugs, 
 antiallergenic drugs; 
 other drugs.  
In total there are 66 positions of drugs in accordance with the data of the State Register of 
Drugs of the Russian Federation (See Appendix 5). As of 2014 ZAO «Severnaya Zvezda» 
manufactured 38 drugs: the list includes 361 SKUs, 6 brands, 12 umbrella brands, 20 INNs. 
The product portfolio is formed on the basis of specific market needs within the relevant 
period.  
The investigation of manufacturing and products sales from 2012 to 2014 was performed 
for the product portfolio analysis. Information for product range analysis were provided by 
the company. On customer request this information is confidential. 
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5.1  Analysis of manufactured products by years 
In 2012, the list of products manufactured comprised 20 positions of drugs: 38 SKUs. There 
were neither brands nor umbrella brands among them. The positions included 20 INNs: 38 
SKUs. The products were manufactured and promoted under the INN concept. (See Figure 
10) 
 
Figure 10. Appearance of products, 2012 
The main trend of 2012 was the renewal of the product range:  
 market launch of three new drugs, namely Pirazinamide tablets, Ribavirin capsules, 
and Methotrexate tablets (4 SKUs); 
 adding new dosage forms; 
 adding new SKUs;  
 expelling of SKUs that are of no demand from the portfolio.  
In 2013, the list of products manufactured comprised 19 positions of drugs: 38 SKUs (See 
Figure 11). There were 2 brands (5 SKUs) and no umbrella brands among them. The 
positions included 17 INNs: 33 SKUs. The company performed rebranding of the package 
design and started working over creation of the new information image of products for the 
purpose to improve brand awareness and trust of consumers, as well as to form loyalty to 
the company. The following range of measures for improvement of the quality of products 
was taken: prolongation of terms of expiration, use of package materials of higher quality. 
39 
 
 
Figure 11. Appearance of products, 2013 
Trends of 2013: 
 low-income product positions were excluded: Verapamil 40 mg tablets, Car-
bamazepine tablets, Loperamide capsules; 
 participation in governmental procurements (Pirazinamide); 
 SKUs of no demand were expelled and new SKUs were added; 
 product range was reviewed: one drug was launched in 3 dosage forms (3 SKUs); 
 branded drugs appeared in the product portfolio of the company (Triducard tablets 
and Ursodez capsules); 
 development of new products and promotion strategies; 
 mastering of new niches (the pharmacological group of Statins); 
 struggle for quality.  
In 2014, the list of products manufactured comprised 25 positions of drugs: 60 SKUs (See 
Figure 12 and Figure 13).There were 5 brands (9 SKUs), 4 umbrella brands (15 SKUs), and 
16 INNs (34 SKUs) among them. The ZAO «Severnaya Zvezda» used umbrella branding 
for the first time to improve the competitiveness of products. The company started to use 
”Forte” products to increase market share. Forte means that the drug has a high 
concentration of active ingredient and prolonged effect. 
Trends of 2014: 
 low-income product positions were excluded: Omeprazol capsules;  
 contract for manufacturing of Loperamide capsules for the CIS countries was re-
started; 
 participation in governmental procurements; 
 SKUs of no demand were expelled and new SKUs were added; 
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 product range was reviewed: expelling of 5 names (12 SKUs); 
 increasing of the share of branded drugs in the product portfolio of the company 
(Korsavin, Pikogam, Allerfex); 
 emergence of umbrella brands in the product portfolio of the company (Amiodaron-
SZ, Ramiprilum-SZ, Ribavirin-SZ, Simvastatin-SZ).; 
 development of new promotion strategies and 6 names of new products; 
 mastering of new niches (the pharmacological group of psychotropic drugs); 
 struggle for quality. 
 
Figure 12. Appearance of products, 2014 
After performance of analysis of products for 2012 to 2014, a number of manufacturing 
names were revealed that were suspended in connection with changes to market conditions. 
The commodity stocks are available at warehouses of the manufacturer, distributors, and in 
the retail chain (See Figure 13). 
 
Figure 13. The product portfolio view, 2014 
Availability of products in portfolio with different way of promotion(brand, umbrella brand, 
INNs) led to the need of restructuring of the portfolio.  
Product Portfolio 
2014 
Brands 
Umbrella 
brands  
INN's 
Commodity 
stocks * 
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5.2  Development of the new product portfolio management model for ZAO «Severnaya 
Zvezda» taking into account the proposed classification 
5.2.1  First Level Product 
Product portfolio is divided into three levels. First level product is considered to be a 
business direction or a group of goods. The product portfolio is allocated 6 first-level 
products, united by a common feature - the therapeutic effect. (See Figure 14) 
 
Figure 14. The first level products of the product portfolio of ZAO «Severnaya Zvezda» 
Analysis conducted nosological (therapeutic) groups with the groups of goods in which the 
company operates. The data were obtained by analyzing the sales structure by ATC groups 
of products. From the overall analysis of the pharmacological market data estimate the 
market volume by nosology: 
 Drugs used for treatment of cardiovascular diseases - Cardio - SZ (See Table 9); 
 Drugs used for treatment of neurological diseases - Neuro - SZ (See Table 10); 
 Drugs used for treatment of gastrointestinal diseases - Gastro - SZ (See Table 11); 
 Drugs acting on the cellular level - "ONCO+" (See Table 12); 
 Drugs used for sexual vigor improvement - Potency (See Table 13); 
 Drugs used for treatment of allergy -Allergy (See Table 14). 
Table 9. Medications used to treat diseases of the cardiovascular system (Cardio) 
Segment of market: Value volume  
mln rub.. 
Share, % Actual volume, 
mln pack 
Share, % 
Commercial segment 64 721 12,6 455 10,8  
Reimbursement segment: 2 521,6 3,0 20,6 30,0 
Hospital segment 7 568,4 3,6 50,7 5,1 
CARDIO
-SZ 
NEURO 
- SZ 
GASTRO 
- SZ 
ONСO+ POTENCY ALLERGY 
Product Portfolio 
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Table 10. Medications used to treat diseases of the nervous system (Neuro) 
Segment of market: Value volume  
mln rub.. 
Share, % Actual volume, 
mln pack 
Share, % 
Commercial segment 59 135 11,5 753 17,8 
Reimbursement segment: 3 418,7 4,1 10,4 15,1 
Hospital segment 18 654,6 8,9 96,4 9,7 
Table 11. Medications used for the treatment of digestive tract diseases (Gastro) 
Segment of market: Value volume  
mln rub.. 
Share, % Actual volume, 
mln pack 
Share, % 
Commercial segment 99 856 19,5 737 17,4 
Reimbursement segment: 13 041,5 15,5 17,5 25,5 
Hospital segment 15 377,2 7,3 81,7 8,2 
Table 12. Medications acting on a cellular level (Onko +) 
Segment of market: Value volume  
mln rub.. 
Share, % Actual volume, 
mln pack 
Share, % 
Commercial segment 19 438 3,2 122 2,9 
Reimbursement segment: 40 828,3 48,4 3,1 4,4 
Hospital segment 18 654,6 8,9 96,4 9,7 
Table 13. Medications used to increase potency (Potency) 
Segment of market: Value volume  
mln rub.. 
Share, % Actual volume, 
mln pack 
Share, % 
Commercial segment 37 447 7,3 82 2,0 
Reimbursement segment: 1 996,2 2,4 0,8 1,1 
Hospital segment 3 266,1 1,6 4,7 0,5 
Table 14. Medications used to treat allergies ("Allergy") 
Segment of market: Value volume  
mln rub.. 
Share, % Actual volume, 
mln pack 
Share, % 
Commercial segment 65 625 12,8 622 14,7 
Reimbursement segment: 5 072,0 6,0 4,9 7,1 
Hospital segment 5 615,6 2,7 32,0 3,2 
In 2014, the volume of the product "Cardio - SZ" was 7.23 million packs, which correspond 
to 1.77% of the market share of cardio products, and 283 million rubles, which corresponds 
to 0.65% of the Russian pharmaceutical market share. The share of commercial market was 
78.1%, while in the state – owned market 21.9%, including in the reimbursement segment 
about 4% and in the hospital segment about 17%. (see Table 9)  
For the analysis of the first level product is used growth-share matrix. 
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Construction of the BCG matrix for the first level products. 
The model proposed to use the BCG matrix for analysis the first level product. The matrix 
allows analyzing the dynamics of market relations and factors. In order to develop the 
strategy of the enterprise as related to the first level product with the help of the BCG, it is 
necessary to calculate the current matrix indicators, build it, reveal strategically unattractive 
products and exclude them, and then build a new BCG matrix. Current indicators for 
building the matrix are set forth in Table 15. The BCG matrix is presented on Figure 15. 
Analysis of the matrix is shown in Table 16. 
Table 15. Current indicators of the first level products for building growth-share matrix 
№ Product: Market growth, % Relative market share,% 
1 «Cardio-SZ» 15,6 0,98 
2 «Neuro-SZ» 12,8 0,05 
3 «Gasto-SZ» 11 0,63 
4 «Onko+» 12 0,04 
5 «Potency» 12 0,006 
6 «Allergy» 0 0,02 
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Figure 15. BCG matrix 
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Table 16. Analysis of the BCG matrix 
№ Product: Market 
growth, % 
Relative market 
share,% 
Diameter: BCGs quadrant 
1 «Cardio-SZ» 15,6 0,98 0,50 Star 
2 «Neuro-SZ» 12,8 0,55 0,15 Star 
3 «Gasto-SZ» 11 0,63 0,2 Star - Cash Cow 
4 «Onko+» 12 0,04 0,12 Question mark 
5 «Potency» 12 0,006 0,06 Question mark 
6 «Allergy» 0 0,02 0,02 Dog 
Out of the products manufactured by the enterprise, Gastro-SZ located at the intersection 
of "Stars" and "Cash Cows" quadrants. In order to save the volume sales of the product at 
the appropriate level the following actions are required: supporting advertising, flexible 
pricing policy, support with the existing distribution network, new modifications of the 
product. The gained profits may be used for support of other products and extension of the 
market share of this product. The priority objective becomes "Harvest". The Cardio-SZ is 
relates to "Stars" quadrant and brings high profit. It is recommended to reinvest most of 
these funds into the Cardio-SZ product to support and develop competitive advantages in 
conditions of growing competition. Neuro-SZ product is also refers to "Stars" quadrant. 
There may be the following strategy options for such products: gradual decreasing of the 
price, increasing of expenses for advertising, development and offer of new product 
modifications, etc. When development becomes slower - "star" will turns into a "cash cow". 
Product “ONCO+” and new product “Potency” are classified as "Wild Cats". Undoubtedly, 
they are prospective as they are launched at fast-growing markets but their promotion 
requires financial costs. In order to get competitive advantages, one needs a promotion 
program that takes into consideration peculiarities of competitors (pricing policy, 
advertising, marketing agreements, etc.). Product “Allergy” is a "Dog". The market of 
antiallergenic drugs is saturated with well-known competitors' products. On the market there 
are four generations of medications, so the consumer generally makes a choice based on 
their own experience in favor of the "old" and "known" drugs. “Allergy” product requires 
significant efforts for its promotion. Due to the fact that the product relates to a low price 
category and has no growth prospects, its further manufacturing is not justified. It is 
necessary to stop financing of the product and to expel it from the product portfolio. A new 
product portfolio is presented in Table 17. The new BCG matrix is shown on Figure 16. 
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Table 17. Performance of the new product portfolio 
№ Product: Market 
growth, % 
Relative market 
share,% 
Diameter: BCGs quad-
rant 
1 «Cardio-SZ» 15,6 0,98 0,50 Star 
2 «Neuro-SZ» 12,8 0,55 0,15 Star 
3 «Gasto-SZ» 11 0,63 0,2 Star - Cash Cow 
4 «Onko+» 12 0,04 0,12 Question mark 
5 «Potency» 12 0,006 0,06 Question mark 
 
Figure 16. New BCG matrix 
5.2.2  Second Level Product  
Second level product is regarded as a trade line inside a group of goods. 18 second level 
products have been distinguished within the product portfolio ZAO ”Severnaya Zvezda” 
and they are united with the common feature - pharmacological action. It includes 7 
products within the Cardio-SZ group, 4 products within the Neuro-SZ group, 4 products 
within the ONCO+ group, 1 product within the Gastro-SZ group, 1 product within the 
Potency group, 1 product within the Allergy group. There may be an unlimited quantity of 
second level products within first level products. In the portfolio such quantity is varied 
from one to seven.  
According to Ministry of Health, the year 2015 dedicated to the fight against heart disease. 
The analysis with matrix method will be on the example of the group of drugs for treatment 
of cardiovascular system diseases. The first level product Cardio-SZ, drugs includes 7 
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directions regarding their pharmacological action. The diagram with consideration of the 
ATC classification can be schematically represented as follows (See Figure 17). 
 
Figure 17. Diagram of the Cardio-SZ second level product 
For the analysis of the second level product are used the ADL and Ansoff matrices. 
Analysis of Second Level Products on the example of the first level product 
Cardio-SZ  
Analysis of second level products was performed through market analysis and studies of 
dynamics. Changes in market shares of pharmacological groups took place due to increase 
of the number of patients,who suffer from various cardiovascular diseases, and by reasons 
of new drugs appearance (new active substances) and joint prescription of drugs from 
various pharmacological groups. For the second level products propose to use Ansoff and 
ADL matrices. The market analysis of the most significant diseases as well as analysis of the 
number of consumers (patients) was performed to make up the matrices. The data is 
presented in Table 18, on Figure 18 and Figure 19. 
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Table 18. Ratio of ATC groups in the volume of pharmacy sales of medicines in Russia in 
April 2014-2015,% 
ATC - groups Products 
of ZAO 
«Severnaya 
Zvezda» 
The share of cost sales 
volume, rub.,% 
The share of the actual 
volume 
sales pack.% 
2014 2015 Shifts in 
market 
share,% 
2014 2015 Shifts in 
market 
share, % 
АAlimentary 
tract and metabolism. 
«Gasto-SZ» 20,08 19,76 -0,32%  18,16 17,44 -0,72 
С Cardiovascular system.  «Cardio-SZ» 12,64 12,82 0,18% 10,63 10,79  0,16% 
R  Respiratory system «Allergy» 11,62 11,28 0,49%  13.49 14.85 1.36%  
N Nervous system  «Neuro-SZ» 11,62 11,28 -0,34% 18,37 16,96 -1,42%  
G Genito-urinary sys-
tem and sex hormones 
«Potency» 7,37  7,17  -0,20%  1,82  1,95  0,13%  
B Blood and blood forming 
organs 
«Cardio-SZ» 3,48 3,70 0,22% 3,04 3,04 0,00% 
L Antineoplastic and 
immunomodulating agents 
«Onko+ 3,69  3,59  -0,09%  1,73  1,53  -0,20%  
The highest growth was demonstrated by the pharmacological groups used for treatment of 
alimentary tract and metabolism diseases. Pharmacological groups for treatment of cardio 
diseases took the II and VIII places on the rating list. The third place on the rating list took 
the pharmacological group for treatment nervous system. Let’s review the pharmacological 
groups used for the treatment of cardiovascular diseases. Combined (joint) therapy is most 
often used for treatment of cardiology diseases, for example, Antihypoxants, 
Antiarrhythmics, ACE Inhibitors, Selective Blockers. Second level products are individually 
selected (prescribed) to each consumer (patient) by their physician.  
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Figure 18. Dynamics of prescribing various pharmacological groups for the treatment of 
cardio diseases 
Dynamics of prescription of products for treatment of blood pressure is set forth on Figure 
19. 
 
Figure 19. Dynamics of prescription of products for treatment of blood pressure 
The dynamics of prescribing pharmacological groups (ATC) 
 С09 – dynamics of the ACE Inhibitors product.  
 С08 – dynamics of Other Products for Reduction of BP. 
 С07 – dynamics of the Selective Blocker product. 
 С10А – dynamics of the Antiarrhythmic product. 
 С10А – dynamics of the Antiaggregant product. 
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Development of the ADL matrix for second level products 
ADL matrix allows planning the strategy for second level products in accordance with the 
stage of life cycle of the Cardio-SZ group of goods (first level product) and the level of 
competitiveness are the market of cardiology drugs. The work with the matrix is performed 
in two stages. The position of the product within the ADL matrix is noted at the first stage: 
the stage of the life cycle of the product and its competitive position at the market is 
determined. The determination parameters of the stage of product development are 
following variables: growth rates, potential of the industry, the breadth of the product range, 
the number of competitors, the stability of market share, the standards of behaviour of 
customers, ease of entry, the level of technological development.  
For instance, the width of the "Antihypoxants" product range in ZAO «Severnaya Zvezda» 
portfolios includes two generations of products regarding their pharmacological and 
technological properties:  
 20 mg film coated tables with usual release of the active substance (discontinued); 
 35 mg film coated tables with modified release of the active substance (still manufac-
tured). 
In the "Antihypoxants" product range 24 names are represented at the market including 12 
brands, 5 umbrella brands, and 7 INNs. It includes 7 foreign manufacturers and 17 domestic 
manufacturers. 
Define the following variables before proceeding to construct the matrix: 
 the first variable of the matrix, which is the market maturity degree;  
 the second variable of the matrix, which is the stability of positions of your company 
in the industry. 
The method was applied to each second level product of the Cardio-SZ group (See 
Appendix 6). Various groups of experts (employees of the company, representatives of 
distributors, and representatives of pharmacy networks) were involved for a more objective 
assessment. Having analyzed the data of second level products, one can develop the matrix 
represented in Figure 20. The strategy is selected in accordance with placement of the 
product in the ADL matrix. 
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Figure 20. ADL matrix for the second level Cardio-SZ product 
In accordance with matrix, the following strategies may be accepted for products. 
The “selective attempt to improve position” strategy is recommended for the group of 
Other Drugs to Reduction of Blood Pressure (BP) for quick market share capturing. Sales 
growth objectives: equal to the market growth value and over it. Competitive advantages: to 
strengthen the current features. It requires selective investment. 
The “attempt to improve position” strategy is recommended for the Antiaggregant group of 
products. Sales growth objectives: to keep the growth equal or a little bit over the market 
growth value. Competitive advantages: to keep the existing product qualities. Average level 
of investments: to keep only the investments that lead directly to market growth.  
The “selective push for share” strategy is recommended for the group of Statins. Sales 
growth objectives: equal to the market growth value. Competitive advantages: to strengthen 
the current features of goods. It requires selective investment. 
The strategy of keeping the niche and market share is recommended for products in groups 
of ACE Inhibitors and Selective Blockers. Sales growth objective is to keep the growth equal 
to the market growth value. Competitive advantages: to keep them on the existing level. 
Invest only in the case of decreasing of sales. 
The “find niche and attempt to protect it” strategy is recommended for the Antihypoxant 
group of products. Sales growth objectives: equal to the market growth value. Competitive 
advantages keep at the current level. Cut down the investments to the minimum required 
level. 
The “phased out withdrawal” strategy is recommended for the Antiarrhythmic group of 
products. No investments.  
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Construction of the Ansoff matrix for the second level products. 
Matrix analysis was performed on example of drugs which normalize the level of cholesterol 
in blood (Statins with the Cardio-SZ group). Analysis of the rest of products was performed 
with the analogous method. The statins product is represented in the portfolio with INN 
Simvastatin. It is represented in the market as follows: 29 INNs including 16 brands, 6 
umbrella brands, and 7 INNs. The products are represented by 22 foreign and 6 domestic 
manufacturers. Included into the VDL list in accordance with the data of 2014, the volume 
of sales comprises 1.03 bln rubles, which is less than 1% of the volume of sales of Vital and 
Essential Drugs in rubles. Commercial market comprises about 3.34 bln rubles. The growth 
of market comprises 7% in monetary terms and 10% in terms of number of packs. The 
Statins product has 6% in monetary terms and 10% in terms of number of packs within the 
product portfolio of the ZAO «Severnaya Zvezda» The product growth rate complies with 
the market growth rate. In accordance with the data of the first quarter of 2015, the growth 
tempo in monetary terms slowed down in connection with appearance of new competitors 
and decreasing of the price for packaging of products (See Appendix 7). On the basis of 
received data build the matrix (See Figure 21) 
 
Figure 21. I. Ansoff matrix for the second level product 
Statins are in the Product Development quadrant. This strategy is possible for the enterprise, 
the risks are minimal, and as the company will be acting at a familiar market. It is 
recommended to take the following measures for its successful implementation: 
 to concentrate on development and widening of the Statins product group: launch of 
new drugs and SKUs; 
 search for new niches: geographical widening and program of joint prescription of 
products of various pharmacological and therapeutic groups (Ursodez® + Statins); 
 extension of marketing agreements with wholesale and retail trading markets; 
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 stimulation of promotion (holding of training sessions with physician and pharma-
cists, participation in exhibitions, etc.).  
5.2.3  Third Level Product 
A third level product is the type of goods that satisfies the needs of a specific consumer or 
has the purpose of treatment of a specific symptom (symptoms) of a disease or ensuring the 
product range of the health care and prevention institutions and pharmacies for satisfying 
such needs. As a rule, all subjects of the pharmaceutics market are aware of the need for 
such product:  
 management and regulation bodies, as a new product (drug) must be registered and 
pass all the required tests regarding efficiency and safety and approved for the use by 
end-consumer; 
 manufacturers as they have developed and approved process regulations, production 
facilities, and manufacturing plan of production and sales of such product (ensures 
supply of such product at the market); 
 distribution structure (distributors and pharmacy networks) as the product must be 
available in the quantity required to satisfy the demand; 
 information resources as the information must be accessible to the consumer (in ref-
erence books, at exhibitions, on the Internet, etc.); 
 physician as they prescribe (recommend) such product; 
 consumers (patients) that use this product. 
A third level product is the type of goods with similar technical and process features that 
may include various types of packaging, filling, and dosage. Several third level products 
comprise a second level product. Allocation of such products is represented in Table 19 for 
the Cardio-SZ first level product with consideration of classification.  
Other products were classified similarly (See Appendix 8,9,10,11,12). 
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Table 19. Cardio-SZ products allocation 
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For analysis of the third level product review INN Simvastatin (See Figure 22). Simvastatin 
has been present at the Russian pharmaceutical market for 8 years. Over the previous 5 year, 
the trend of decreasing of the market share has been observed due to entering of new 
generation drugs to the market. Thus, during 2010 to 2014, the share of Simvastatin was 
decreased in the governmental segment from 56.4 percent to 29.0 percent, and from 43.0 
percent to 14.8 percent in the commercial segment. (The newspaper "Pharmaceutical 
Bulletin", 2015) 
The following trends are observed regarding the Simvastatin INN data in the portfolio of 
ZAO «Severnaya Zvezda»:  
 the growth of sales comprised 6% in packs and 9% in rubles during the period of 
2012 to 2013; 
 the growth of sales comprised 1.2 % in packs and 2% in rubles during the period of 
2013 to 2014. 
The growth of sales was caused with the pricing policy and shaking weaker players out of 
the market.  
 
Figure 22. Third level product INN Simvastatin of ZAO «Severnaya Zvezda» product 
portfolio 
Analyze Simvastatin INN product with the BCG matrix algorithm for the 1 half-year of 
2015 is represented on Table 20 and Figure 23. 
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Table 20. Current figures for INNs "Simvastatin" 
Product Volume 
Value, 
thousand rub  
Market 
growth, 
% 
Market share, % Relative 
market 
share, % 
D
ia
m
e
te
r BCG 
quadrant 
2014 2013 Severnaya 
Zvezda 
Zodak
* 
INN 
Simvastatin 
60978 5209
8 
1,2 6 17 0,35 0,06 Cash cow 
* The leading competing product in the current market  
 
Figure 23. BCG Matrix of product "INN Simvastatin" 
The product INN Simvastatin is refers into the "Cash Cow" quadrant. In order to keep the 
product sales volumes on the right level required: supporting advertising, flexible pricing 
policy, geographical extension of the sales network, new modifications of the product. The 
gained profits may be reinvested into the product, into other current products, into new 
products, and into the search for new niches. The priority objective becomes "Harvest". 
In 2012, the company performed market analysis and revealed the trend of decreasing of the 
Simvastatin share at the market of Statins. For selection of the objective product support 
strategy analyze the market of Statins. The Statins group includes the following active 
substances: Atorvastatin, Lovastatin, Pravastatin, Rosuvastatin, Simvastatin, etc. 
Atorvastatin, Rosuvastatin, and Simvastatin hold a significant share at the Russian 
pharmaceutical market. 
Simvastatin is represented at the market as follows: 29 INNs including 16 brands, 6 umbrella 
brands, and 7 INNs. The products are represented by 22 foreign manufacturer and 6 
domestic manufacturers (State Register of medicines, 2015). Included into the list of Vital 
and Essential Drugs in accordance with the data of 2012, the volume of sales comprises 1.03 
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billion rubles, which is less than 1 percent of the volume of sales of Vital and Essential 
Drugs in rubles. Commercial market volume of Simvastatin comprises about 3.34 billion 
rubles. 
Atorvastatin is represented at the market as follows: 25 INNs including 17 brands, 4 
umbrella brands, and 4 INNs. The products are represented by 17 foreign manufacturer and 
8 domestic manufacturers (State Register of medicines, 2015). Included into the list of Vital 
and Essential Drugs in accordance with the data of 2012, the volume of sales comprises 2 
billion rubles, which is 1.55 percent of the volume of sales of Vital and Essential Drugs in 
rubles. Commercial market volume of Atorvastatin comprises about 10.77 billion rubles  
Rosuvastatin is represented at the market as follows: 11 INNs including 9 brands and 2 
umbrella brands. The products are represented by 7 foreign manufacturer and 4 domestic 
manufacturers (State Register of medicines, 2015). Not included into the list of Vital and 
Essential Drugs. According to the data of 2012, the volume of sales at the commercial 
market comprised 20 billion rubles; according to the data of 2013, the volume of sales at the 
commercial market comprised 24 billion rubles.  
The market of Statins of 2007: Simvastatin: about 52 %; Atorvastatin: about 29%; 
Rosuvastatin: about 4 %; other Statins: about 15% (See Figure 24). Other Statins were not 
reviewed in the analysis.  
 
Figure 25. Shares of medications of the Statins pharmacological group, (DSM Group) 
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Changes of the share of drugs of the Statins pharmacological group for the period of 2013 
to 2014 by market segments: 
 share of Simvastatin dropped in the commercial segment from 21,3% to 14,8 %, and 
in the governmental procurements segment it dropped from 32,5% to 29%; 
 share of Atorvastatin has remained quite high for the previous 3 years (about 40%) 
and continues to demonstrate regular growth in the both market segments. In the 
segment of government procurements, its share grew from 48,3% to 52,%. The 
commercial segment demonstrated insignificant drop of share from 48,2% to 47,9%. 
Changing of the share in the commercial segment is caused with the fact that many 
foreign and domestic manufacturers have entered the market. The market share in 
packs has not changed. 
 share of Rosuvastatin rose in the commercial segment from 20,2 % to 29,2%, and in 
the governmental procurements segment it rose from 9,7% to 13,4%. 
Based on the performed analysis, it is recommended to reinvest the profits from Simvastatin 
INN into the following programs. Support “INN Simvastatin”: perform rebranding into an 
umbrella brand to keep the market share. Invest part of profits into development, 
registration, and market launch of a new product with new active ingredient “Atorvastatin”, 
the market of which is mature, with a developed competitive structure. Market growth in the 
segment of governmental procurements is observed. The strategy of quick market launch, 
promotion, cooperation with physicians and pharmacists, use of the umbrella brand is 
required. As there are domestic manufacturers at the market, immediately after market 
launch the product may take the share of about 1%  in the commercial segment and about 
5%  in the governmental segment. Invest part of profits into development, registration, and 
market launch of a new product with new active ingredient “Rosuvastatin”. The market is at 
the stage of growth with not yet formed competitive environment. The strategy of quick 
market launch, promotion, active use of marketing agreements with pharmacy networks, use 
of the umbrella brand is required. There is only one domestic manufacturer at the market, so 
immediately after market launch the product may take the share of about 4% in the 
commercial segment and about 10%  in the reimbursement segment. 
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Development of the ADL Matrix for Third Level Products 
ADL matrix allows planning the strategy for both second and third level products in 
accordance with the stage of life cycle of the Cardio-SZ segment (first level product) and the 
level of competitiveness are the market of cardiology drugs. The tables similar to the tables 
for second level products were used for the analysis. For a more objective assessment of the 
strategy accepted for portfolio management, the matrix of third level products may be 
imposed onto the matrix of second level products. Such methodology may be applied for 
analysis of products at the same market segment (e.g. Cardio-SZ). The joint matrix is 
presented on Figure 26. 
 
Figure 26. ADL Matrix of the Cardio-SZ third level products 
In accordance with ADL matrix, the following strategies may be accepted for third level 
products. 
The “selective attempt to improve position” strategy is recommended for the Moxonidine 
product. One should wait for the favorable situation for quick capturing of the market share. 
Sales growth objectives: equal to the market growth value and over it. Competitive 
advantages: to strengthen the current features of goods or services. Selective investments are 
to be made only into the projects capable of significant improvement of the company in the 
industry. 
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The strategy of holding positions is recommended for the Clopidogrel and Ramipril 
products. Sales growth objectives: to keep the growth equal or a little bit over the market 
growth value. Competitive advantages: to keep the existing product qualities. Average level 
of investments: to keep only the investments that lead directly to market growth.  
The “selective push for share” strategy is recommended for the Simvastatin and Felodipin 
products. One should wait for the favorable situation for quick capturing of the market 
share. Sales growth objectives: equal to the market growth value. Competitive advantages: to 
strengthen the current features of goods or services. Selective investments only into the 
capable projects for significant improvement of the company in the industry. 
The “find niche and protect it” strategy is recommended for the Nebivolol product. Sales 
growth objectives: equal to the market growth value. Competitive advantages: to strengthen 
the current features of goods or services. Selective investments only into the capable 
projects for significant improvement for the company in the industry. One must be careful 
with investments - the risk of low return on investment is increased. 
The strategy of holding positions and keeping the market share in the segment is 
recommended for the Perindopril and Bisoprolol products. Sales growth objectives: to keep 
the growth equal to the market growth value. Competitive advantages: to keep them on the 
existing level. Only invest in the case of decreasing of sales. 
The “find niche and hang on” strategy is recommended for the Trimetazidin product. Sales 
growth objectives: equal to the market growth value. Keep the competitive advantages on 
the existing level. Cut down the investments to the minimum  
The holding positions strategy is recommended for the Lisinopril product. Sales growth 
objectives: to withstand dropping for the maximally long time. Cut down expenses for 
maximization of profits. If possible, refrain from reinvestments. 
The “phased out withdrawal” strategy is recommended for the Amiodaron product. No 
investments and p reparation to leaving the market. 
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Additional Analytical Study of the Potency Product 
A prospective direction of market development is potency regulation drugs, which were 
revealed in the course of analysis of the market in 2010 to 2014. A representative of this 
segment is Viagra brand, INN Sildenafil. The expiration date of patent protection in May 
2014. Data provided by the company. The company took the solution to develop the INN 
Sildenafil drug, register it, and launch it to the market. As launching of the product to 
market takes four years, additional studies are necessary for determination future position of 
the product and promotion strategy. In 2014 Sildenafil was represented in the Russian 
Federation with three drugs (See Table 21). 
Table 21. INNs market: Sildenafil in Russia, 2014  
Product Manufacturer Dosage SKU 
Price per pack. rub. 
(4 tablets) 
Viagra Pfizer, Germany 
100mg 5 2663 – 2745 
50mg 2275 – 2325 
25mg 996 – 1091 
Sildenafil Pliva, Croatia 
100mg 4 778 – 792 
50mg 505 – 585 
Dinamika Teva, Israel 
100mg 4 654 – 710 
50mg 497 – 553 
According to State Register of medicibes, all foreign manufacturers have brands to make 
promotion of the drug easier, and it is proposed to use the INN to cut down the costs. The 
following dosage is recommended for manufacturing: 25 mg, 50, mg, 100 mg. Availability of 
SKU with the dosage of 25 mg will guarantee big market share to our product and make it 
competitive with the main competitive (Viagra). Price is one of the competitive advantages 
of the drug manufactured by ZAO «Severnaya Zvezda». 
Were developed the general recommendations regarding third level products. Technological 
and qualitative changes of the current products at the current market must be developed for 
the purpose of getting new consumer properties (FORTE drugs (increasing of dosage), 
drugs with modified release of active ingredient, drugs with prolonged release, etc.). Analysis 
must be performed and measures must be developed for entering new markets (geographical 
extension). In connection with the fact that patients (consumers) usually have several 
diseases or symptoms, studies must be performed and joint prescription of third level 
products of various pharmacological and therapeutic groups must be recommended 
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(gastro+cardio, cardio+cardio); corresponding strategy of joint promotion must be 
developed. The number of SKUs must be optimized for the purpose to cut down the costs 
(bigger packs for hospital segment). Investments must be made into promotion and creation 
of a new information image. Individual approach to pricing strategy must be developed for 
each product with consideration of its competitive environment and planned volume of 
investments.  
АBС, ZYX, АBС+ZYX methods of product range analysis may be applied for development 
of analysis inside INNs. 
In the thesis were determined strategies for 2016 to 2018, described measures required for 
their implementation, and determined financial costs The assessment of economic efficiency 
of implementation of the product portfolio management model  can be found in the 
Appendix 13.  
5.3  The results of the economic evaluation of the introduction of a new product portfolio 
management model for the enterprise ZAO «Severnaya Zvezda». 
The project reviewed regarding improvement of the product portfolio of active enterprise 
for manufacturing of drugs, ZAO «Severnaya Zvezda» efficient. 
The project will allow extension and optimization of the product range and will bring the net 
profit of 44 million 174 thousand rubles during 4 years of its implementation. The rate of 
return from investment will comprise 2 (i.e., every 2 rubles invested into production facilities 
will bring 2 rubles of net profits from sales of ready products). The payback period of the 
project is 2 years and 3 months, which is less than the period of implementation of the 
project itself (i.e., the project will be paid back in half of the term of its implementation).The 
received indicators allow making the conclusion that the project is efficient and must be 
introduced at the enterprise. 
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6  RECOMENDATIONS & CONCLUSION 
In this thesis has been studied theoretical aspects of formation and management of the 
product portfolio with consideration of rapid changes of the environment. Based on 
research was improved portfolio management model for the pharmaceutical company, 
which takes into account the nuances and limitations of the industry. They include economic 
sanctions and strict state regulation of production and prices. 
The main goal of the thesis was to develop new algorithm of the product portfolio 
management. As a result were developed specific practical recommendations for 
pharmaceutical companies. The proposed model was experimentally verified on the basis of 
close joint stock pharmaceutical enterprise ZAO «Severnaya Zvezda».  
The developed provisions may be considered as a methodological basis for taking 
management solutions at various management levels. The system of main components of 
the product portfolio has been developed in the case study, which may be used for 
assessment of efficiency of the current portfolio, as well as for determination of 
development of the product portfolio. The model allows making the optimum plan of 
manufacturing and promotion of products in accordance with consumers' requests and 
cutting down expenses of the enterprise.  Depending on the role of products in portfolio, 
they were grouped and classified in accordance with their characteristics. The use of matrices 
provides visual presentation of the "contribution" of individual products to the overall 
financial result for a certain period. The model allows simplifying multi-component 
portfolios by exclusion of many secondary factors from reviewing, which makes portfolio 
assessment simpler and more understandable. 
The following strategies have been proposed for ZAO «Severnaya Zvezda» portfolio 
management based on the forecast of the market: 
 development of first level products with consideration of development of market 
segments and selection of new prospective directions; 
 development of new generations products; 
 perfection of technological and qualitative characteristics of current products at cur-
rent markets for the purpose of getting new consumer properties; 
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 entering to new markets (geographical extension); 
 joint promotion of various products (gastro+cardio); 
 price strategy for each product with consideration of its competitive environment 
and planned volume of investments. 
These recommendations for product portfolio management take into account and used on 
enterprise ZAO «Severnaya Zvezda». (See Appendix 14). 
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Appendix 1. The current situation on the Russian market. 
According to DSM Group, at the end of 2014, the volume of Russian pharmaceutical 
market amounted to 1152 billion rubles in the prices of final consumption, which is 10% 
more than in 2013. Comparison of market volume is presented in Table 1.  
Table 1. Comparison of volume of the Russia pharmaceutical market 2013 - 2014 
Market Market 
size in 
terms of 
value 
(cost) 
2013, 
bln rub 
Market size 
in terms of 
natural 
product 
2013,  
bln pack. 
Market 
size in 
terms of 
value 
(cost) 
2014,  
bln rub 
Growth, 
% 
Market size 
in terms of 
natural 
product 
2014,  
bln pack. 
Growth, 
% 
Commercial  
market 
609  4,4 975 11% 4,2 -4.5% 
State market 267  294,2 10,2%   
Hospital seg-
ment 
84,4  84,4    
Reimbursement 
segment 
182,6  209,8 15%   
TOTAL 1 045  1 152    
The capacity of the commercial market in 2014 amounted to 975 billion rubles in the prices 
to final consumption, or 513 billion rubles in pharmacy purchase price (See Table) which is 
11% more than in 2013. It was realized 4.2 billion packages, which is 4.5% less than in 2013. 
The share of the State-owned segment (Hospital + Reimbursement) was about 25.5%. As a 
result, ¾ of the pharmaceutical market is realized at the expense of own funds of the 
population. The graphs of Figure 1 show the dynamics of the volume of the Russian 
pharmaceutical market in 2012-2014 in retail prices. 
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*Para pharmaceutical segment is not included in the case study 
Figure 1. Capacity of the Russian pharmaceutical market, bln rubs. 
In 2014, the commercial segment of medications is growing at a rate comparable to the 
growth of the market as a whole and with the state segment. Government policy in public 
drug supply of the population remains the same, and articles that bear a social character, 
does not decrease. Over 2014 growth in ruble terms Hospital and Reimbursement segments 
accounted for 10% (DSM Group, 2015).  
The main driver of market growth is inflation. It is comparable to the State Statistics 
Committee index of consumer prices, and on the basis of 2014 price increases for drugs 
amounted to approximately 12.7% (which is significantly higher than in previous years). 
Packages commercial segment of medicines shows a negative trend. Such dynamics is caused 
by a decrease in sales of products in the price range up to 50 rubles (50% loss in market 
volume fall on this segment). However, this factor has several reasons: on the one hand, 
consumers are placing more demands on the quality of medicines and prefer a more 
expensive drug. On the other hand, inflation in this segment is the highest - almost 28%. 
This leads to the fact that consumers are not buying the "traditional" cheap drugs for the 
future, which is also a reason for the change of the market structure (DSM Group, 2015). 
New medicines are launched to the market every year. According to the State Registry of 
Pharmaceutical Drugs more than 28000 of medicinal product have been registered in the 
territory of Russia. The market is saturated not mainly by new original substances 
(innovators), but by already familiar substances (generics). Substances, having the same 
Active Pharmaceutical Ingredient API are often hidden by different trade names. Actually, 
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this is the same substance. For example, there are 32 synonyms of aspirin, more than 20 of 
Analgine, 38 of Paracetamol (State Register of medicines, 2015).  
More than half of the registered drugs on the market make up the "top group", which 
consist of five-six pharmaceutical groups drugs out of 30 according to the International 
Classification of Diseases. These medicines are for the treatment of infectious diseases, 
cardiovascular, gastrointestinal diseases, analgesics, antipyretics, nonsteroidal anti-
inflammatories, hormonal agents. However, an insufficient number of individual 
pharmacological groups of drugs are registered for treatment of rare or social diseases. 
COMMERCIAL SEGMENT 
In value terms, the share of domestic drugs is about ¼ of the Russian commercial market of 
medicines and in 2014 amounted to 24.3%. At the same time domestic drugs prevail in retail 
sales in volume terms - 55.3%. Note that in 2014 the share of domestic drugs in packages 
has decreased by almost 2%. The increase in sales of imported drugs was equivalent to the 
increase in domestic sales volume of drugs in value: + 11% by foreign drugs and 10% by 
Russian agents. In natural terms, sales of Russian drugs decreased by 7.6%, while for 
imported products reduction amounted about 0.5%. The structure of the commercial 
market in terms of sales of domestic and imported products is reflected in Figure 2. 
 
Figure 2. The sales ratio of imported and domestic drugs of commercial market in 
pharmacies prices, 2014 (DSM Group, 2015) 
At the end of 2014 the commercial market of drugs in value terms increased sales of both 
prescription and non-prescription drugs. Typically, sales of Rx drugs are growing at a higher 
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rate than sales of OTC drugs. According to DSM Group data, sales of Rx-drugs grew in 
rubles by 12.7%, while OTC drugs sales growth was 8.9%. In natural terms also recorded 
similar dynamics; "-6.0%" - an increase in sales of OTC drugs, and "1%" – growth of RX- 
drugs. The share of Rx drugs in rubles amounted to 50.1%; in natural terms is dominated by 
OTC drugs (69.6%). Note that the average value of Rx-drugs was 200 rubles, while the price 
of OTC-drugs, on average, 2.5 times less - 87 rubles per pack. The ratio of the volume of 
pharmacy sales of Rx and OTC drugs is shown in Figure 3. 
 
Figure 3. The sales ratio of OTC and Rx drugs of retail commercial market in Russia, 2014,  
(DSM Group, 2015) 
The structure of the commercial market by ATC-groups each year is relatively stable. Value 
of pharmacy sales by first level of ATC groups in Russia is presented in the Table 2. 
Table 2. Structure of sales of Russian Commercial market by ATC-groups, 2014 
ATC groups of I level 
Market 
size in 
terms of 
value 
(cost), mln 
rub. 
Share 
of the 
group 
in 
market 
size, % 
Market 
size in 
terms of 
natural 
product, 
mln 
pack. 
Share 
of the 
group 
in 
market 
size, % 
Code Contents 
A Alimentary tract and metabolism 99 856 19,5% 737 17,4% 
R Respiratory system 65 625 12,8% 622 14,7% 
C Cardiovascular system 64 721 12,6% 455 10,8 
N Nervous system 59 135 11,5% 753 17,8% 
J Antiinfectives for systemic use 40 911 8,0% 290 6,9% 
M Musculo-skeletal system 40 350 7,9% 281 6,7% 
G Genito-urinary system and sex hormones 37 447 7,3% 82 2,0% 
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ATC groups of I level 
Market 
size in 
terms of 
value 
(cost), mln 
rub. 
Share 
of the 
group 
in 
market 
size, % 
Market 
size in 
terms of 
natural 
product, 
mln 
pack. 
Share 
of the 
group 
in 
market 
size, % 
Code Contents 
D Dermatologicals 31 825 6,2% 445 10,6% 
L Antineoplastic and immunomodulating 
agents 
19 438 3,2% 122 2,9% 
B Blood and blood forming organs 17 430 3,4% 60 1,4% 
~ Medicaments, without ATC-group 16 053 3,1% 210 5,0% 
S Sensory organs 13 383 2,6% 103 2,4% 
H Systemic hormonal preparations, excluding 
sex hormones and insulins 
2 902 0,6% 25 0,6% 
V Various 2 520 0,5% 18 0,4% 
P Antiparasitic products, insecticides and 
repellents 
1 491 0,3% 19 0,5% 
In 2014 the leading position, as in previous years, retained products of ATC - group [A] 
«Alimentary tract and metabolism» (19,5%), [R] «Respiratory system» (12,8%), [C] 
Cardiovascular system (12,6%), [N] Nervous system (11,5%) and [J] Antiinfectives for 
systemic use (8%). TOP-3 groups of drugs amounted about 50% of the market growth as a 
whole (DSM Group, 2015). State-owned segment 
STATE SEGMENT: Hospital Subsegment  
According to the dynamics of hospital purchases by quarters, in second half of the year 
purchases increased. (See Figure 4) In 2014, total costs reached 209,8 bln rub., which is 
14,8% more than in 2013.  
 
Figure 4. Dynamics of hospital purchases by quarters 
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An increase of purchases in Q4 2014 is explained by high growth of rates. Purchases of 
hospitals relatively the Q4 2013 increased by 26% in value terms and 13% in term of natural 
product. Thus, the hospital made a medicines stock for 1st quarter of 2015. (See Figure 5) 
The volume of purchases of imported drugs in 2014 has grown in rubles 12% of domestic 
products increased by 23%. In natural product terms, the volume of imported drugs 
purchases dropped by 1%, while domestic - increased by 6%. As in the previous year, the 
segment in value terms is dominated by imported products, while the volume of packages in 
the lead domestic drugs. The cost of one pack of imported medicines almost 8 times higher 
than the cost of one package purchased from domestic producers. In 2014, one imported 
packaging an average cost 575 rbl and domestic only 72 rbl. According to the current dollar 
exchange rate 1 dollar = 60 rubles it is approximately 9.5 dlr and 1,2 dlr. Thus domestic 
products occupy about 25% of the volume in terms of value and 73% in terms of natural 
product (DSM Group, 2015). 
 
Figure5. The sales ratio of imported and domestic medicines in Hospital segment 
Rating of medicines of Hospital segment by ATC groups is significantly different from the 
commercial market. Rating ATC groups in comparison with 2013 has not changed. The 
sales structure of the segment by ATC-groups is presented in the Table 3. 
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Table 3. The sales structure of the Hospital segment by ATC-groups, 2014 
ATC groups of I level Market 
size in 
terms of 
value 
(cost), mln 
rub. 
Share 
of the 
group 
in 
market 
size, % 
Market 
size in 
terms of 
natural 
product, 
mln 
pack. 
Share 
of the 
group 
in 
market 
size, % 
Code Contents 
J Antiinfectives for systemic use 73 902,3 35,2% 289,3 29,0% 
B Blood and blood forming organs 34 362,9 16,4% 325,6 32,6% 
L Antineoplastic and immunomodulating 
agents 
29 941 8,9% 96,4 9,7% 
N Nervous system 18 654,6 8,9% 96,4 9,7% 
A Alimentary tract and metabolism 15 377,2 7,3% 81,7 8,2% 
V Various 9 013,8 4,3% 11,6 1,2% 
C Cardiovascular system 7 568,4 3,6% 50,7 5,1% 
R Respiratory system 5 615,6 2,7% 32,0 3,2% 
M Musculo-skeletal system 4 741,9 2,3% 21,9 2,2% 
G Genito-urinary system and sex hormones 3 266,1 1,6% 4,7 0,5% 
H Systemic hormonal preparations, excluding 
sex hormones and insulins 
2 454,8 1,2% 14,5 1,5% 
S Sensory organs 2 025,4 1,0% 6,6 0,7% 
D Dermatologicals 1 860,2 0,9% 50 5,0% 
~ Medicaments, without ATC-group 976,5 0,5% 2 0,2% 
P Antiparasitic products, insecticides and 
repellents 
47,2 0,0% 0,4 0,0% 
The leading groups of drugs according to the ATC classification in the hospital segment by 
the end of 2014: 
 [J] Antiinfectives for systemic use; 
 [B] Blood and blood forming organs; 
 [L] Antineoplastic and immunomodulating agents; 
 [N] Nervous system; 
 [A] Alimentary tract and metabolism; 
STATE SEGMENT: Reimbursement subsegment  
Additional medicinal provision of certain categories of citizens is one of the measures of 
social support for population. The Reimbursement program mostly "imported", the 
domestic production takes small place in amount of drugs. The main task of the government 
according to the program "Pharma 2020" is to cardinally reverse this situation: the result is 
to increase the share of domestic products to 50%. Therefore, in the market, and in 
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particular the program providing preferential drugs there is a tendency to the appearance of 
an increasing number of home agents that are able to replace imported analogs. 
At the end of 2014 the share of domestic products in terms of value decreased by 1% (See 
Figure 6). The increase in costs for the domestic medicines purchases decreased by 9.2% 
while consumption of imported products increased by 0.9%. The ratio is maintained for the 
benefit of imported drugs: 87% of the value of imported products account for the origin 
and 13% for domestic drugs. In natural product terms, the share of domestic medications 
for the first few years has increased (+ 2%). However while maintaining a downward trend 
in packages sales of both domestic and imported drugs: in 2014 the sales of domestic 
products fell by 4%, imports by 12%. 
 
Figure 6. The sales ratio of imported and domestic medicines in Reimbursement segment 
According to report of DSM Group, in the first three months of 2015 were purchased 25.8 
million packages of drugs in the amount of 48.7 billion rubles. Compared with the first three 
months of last year the volume of purchases in packages unchanged (+ 0.02%), and in 
rubles increased by 25.1%. In 2015, the decline in volume of purchases in packages of 
medicines domestic production is 10.7%. Imported medicines were purchased on 9.9% 
more. About 50% in the value of the purchase is necessary, as in the last year, antineoplastic 
and immunomodulation agents’ medications. 
The structure of the top five by ATC groups in 2014 has not changed compared to the year 
2013: the share in value volume was about 89%. The structure of the reimbursement 
segment by ATC-groups in Russia is presented in the Table 4. 
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Table 4. The sales structure of Russian Reimbursement segment by ATC-groups, 2014 
ATC groups of I level Market 
size in 
terms of 
value 
(cost), mln 
rub. 
Share 
of the 
group 
in 
market 
size, % 
Market 
size in 
terms of 
natural 
product, 
mln 
pack. 
Share 
of the 
group 
in 
market 
size, % Code Contents 
L Antineoplastic and immunomodulating 
agents 
40 828,3 48,4% 3,1 4,4% 
A Alimentary tract and metabolism 13 041,5 15,5% 17,5 25,5% 
B Blood and blood forming organs 12 213,8 14,5% 5,1 7,4% 
R Respiratory system 5 072,0 6,0% 4,9 7,1% 
N Nervous system 3 418,7 4,1% 10,4 15,1% 
C Cardiovascular system 2 521,6 3,0% 20,6 30,0% 
H Systemic hormonal preparations, excluding 
sex hormones and insulins 
1 996,2 2,4% 0,8 1,1% 
J Antiinfectives for systemic use 2 208,6 2,6% 0,7 1,1% 
M Musculo-skeletal system 1 196,5 1,4% 2,7 3,9% 
V Various 964,1 1,1% 0,3 0,5% 
G Genito-urinary system and sex hormones 429,5 0,5% 0,9 1,3% 
~ Medicaments, without ATC-group 282,5 0,3% 0,2 0,2% 
S Sensory organs 197,2 0,2% 1,5 2,1% 
D Dermatologicals 21,0 0,0% 0,2 0,2% 
P Antiparasitic products, insecticides and 
repellents 
1,0 0,0% 0,0 0,0% 
 
The leading groups of drugs according to the ATC classification in the segment by the end 
of 2014 are: 
 [L] Antineoplastic and immunomodulating agents; 
 [A] Alimentary tract and metabolism; 
 [B] Blood and blood forming organs; 
 [R] Respiratory system 
 [N] Nervous system; 
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MANUFACTURERS 
Currently, in the Russian Federation on the basis of Russian Industry and Trade Ministry 
have about 1000 drug manufacturers. The TOP-15 is presented in Table 5. In 2014 
cumulative their share was 53,5%. The first places in the ranking of manufacturers occupy 
foreign companies: NOVARTIS, SANOFI and BAYER. On the fourteen line is 
OTISIPHARM (ex PHARMSTANDART) - the only domestic manufacturer of the top 20 
leading players in the Russian pharmaceutical market. In 2013 domestic manufacturer of 
pharmaceuticals PHARMSTANDART took 3rd place in TOP-20 leading companies in 
Russian market. At the end the year there was a reorganization of "PHARMSTANDART" 
in two companies: OTISIFARM and PHARMSTANDART. As a result, OTISIFARM 
ranked 14th and PHARMSTANDARD ranked 21th.  
Table 5. Top 20 leading manufacturers in the Russian pharmaceutical market 2014 
Rating 
Manufacturers 
Value  
volume, 
mln rub. 
2014 
Growt, 
% 
Share of 
the 
market, 
% 
 2
0
13
 
 2
0
14
 
1 1 NOVARTIS Swiss 57 154 7,0% 5,9% 
2 2 SANOFI France 51 751 8,3% 5,4% 
4 3 BAYER Germany 38 136 9,6% 4,0% 
6 4 TAKEDA Japan 30 303 13,0% 3,1% 
5 5 TEVA Israel 28 881 2,6% 3,0% 
9 6 JOHNSON&JOHNSON USA 27 702 16,2% 2,9% 
7 7 F.HOFFMANN-LA ROCHE Swiss 27 201 -0,5% 2,8% 
15 8 SERVIER France 27 043 9,0% 2,8% 
8 9 ABBOTT USA 26 007 5,4% 2,7% 
13 10 PFIZER USA 24 285 44,7% 2,5% 
 11 BERLIN-CHEMIE Germany 21 940 3,7% 2,3% 
11 12 MERCK USA 20 451 15,8% 2,1% 
12 13 GLAXOSMITHKLINE UK 19 911 7,7% 2,1% 
3 14 OTISIPHARM Russia 19 458 3,5% 2,0% 
14 15 GEDEON RICHTER Hungary 18 299 7,2% 1,9% 
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Appendix 2. The volume of Russian pharmaceutical market compared to other 
countries. 
In 2014, the volume of the global pharmaceutical market reached 1.06 trillion US dollars. In 
comparison with 2013 it grew in monetary terms amounted to about 7%. Traditionally the 
fastest growing markets are the countries of Latin America and China. At the end of 2014, 
Russia was on the 7th place among the world's leading pharmaceutical markets, but due to 
the weakening of the ruble in dollar terms the market capacity was reduced by 8%. If 
dynamics continues, in 2015 Russia might shift 1-2 places down (DSM Group, 2015). The 
volume of pharmaceutical market in the world is presented on Figure 1. 
 
Figure 1. The volume of retail market of Russia and other countries in 2014 
The biggest pharmaceutical market is in USA. Only the retail sale of medicines makes up 
256.4 billion dollars. European markets (Top 5) together make up 109.5 billion dollars (10% 
of capacity in the world market) and in 2014 grew by 3%. Russia lags behind average 
European level of medicines consumption by 3 times and 5 times from the consumption in 
United States. Less than in Russia ($141) consumption of drugs per person only in Brazil 
($122) and China ($ 52) (See Figure 2). 
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Figure 2. The consumption of medicines in the world, 2014 
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Appendix 3. The Certificate of GMP. 
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Appendix 4. The license for production.
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Appendix 5. The list of products manufactured by ZAO ”Severnaya Zvezda” in 2015. 
№ Name Pharmacological group 
 
Allerfeks, coated tablets 30 mg, 120 mg and 180 
mg 
Antihistamines 
 Amiodarone-SZ, tablets 200 mg  Antiarrhythmics 
 Acyclovir, tablets 200 mg  Antiviral agents 
 Betahistine, tablets 8 mg, 16 mg and 24 mg Angioprotektory and proofreaders microcirculation 
 Bisoprolol, film-coated tablets, 5 mg and 10 mg Beta-blockers 
 Verapamil, film-coated tablets, 80 mg Calcium channel blockers 
 Verapamil, film-coated tablets, 40 m Calcium channel blockers 
 Digoxin, tablets 0.25 mg  Cardiac glycosides and non-glycoside cardiac facilities 
 Carbamazepine, tablets 200 mg  Antiepileptics 
 Clopidogrel, film-coated tablets 75 mg Platelet aggregation inhibitors 
 Korsavin®, tablet 5 mg Proofreaders disorders of cerebral circulation 
 Korsavin® Forte Tablets 10 mg Proofreaders disorders of cerebral circulation 
 Lisinopril, tablets 5 mg, 10 mg and 20 mg ACE inhibitors 
 loperamide, capsules 2 mg  Antidiarrheals 
 Meloxicam SZ, tablets 7.5 mg and 15 mg NSAIDs - Oxicams 
 Metoclopramide, tablets 10mg Stimulants gastrointestinal motility (antiemetic) 
 Methotrexate, film-coated tablets 2.5 mg Antimetabolites 
 Olanzapine, film-coated tablets 5 mg and 10 mg Antipsychotics 
 Omeprazole, capsules 20 mg Proton pump inhibitors 
 
Pentoxifylline, tablets, coated with enteric shell, 
100 mg 
Antiplatelet agents; Adenozinergicheskie tools; Angioprotektory 
and proofreaders microcirculation 
 Perindopril, tablets 2 mg, 4 mg ACE inhibitors 
 PikogaM®, tablets 50 mg Nootropics, Proofreaders disorders of cerebral circulation 
 Pyrazinamide, tablets 500 mg  Synthetic antibacterials 
 Piracetam, capsules 400 mg  Nootropy 
 
Ramipril-SZ, tablets 2.5 mg,  
5 mg and 10 mg 
ACE inhibitors, ACE inhibitors in the combinations of calcium 
channel blockers in combination 
 Ranitidine, film-coated tablet 150 mg Antihistamines 
 Ribavirin-SZ, capsules 200 mg  Antiviral (excluding HIV) agent 
 Riboxinum, film-coated tablets 200 mg Anabolic 
 
Simvastatin SZ, film-coated tablets 10 mg, 20 
mg and 40 mg 
Statins 
 Tamoxifen tablet 10 mg 
Estrogens, progestins; antagonists, and their homologs, antineo-
plastic hormones and hormone antagonists 
 
Triduktard®, film-coated with modified release 
tablets 35 mg 
Antihypoxants and antioxidants 
 Tricho - PIN tablets 250 mg Synthetic antibacterials 
 Ursodez® Capsules 250 mg 
Hepatoprotectors, Cholagogue and preparations bile, other li-
pid-lowering drugs 
 Furagin tablets 50 mg Synthetic antibacterials 
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Appendix 6. Analysis of the second level product by the ADL matrix.  
№ Question 
Industry life cycle stage 
Embryonic Growing Mature Aging 
ASSESSMENT OF MARKET MATURITY 
1 
How fast growing market of 
the product? 
rapid growth moderate growth not growing, stagnates falls 
0 1 0 0 
2 
How high is the market poten-
tial? 
very high, the market being 
formed 
moderately high insignificant, almost peaked  
no potential, the  
market peaked 
0 1 0 0 
3 
What is the consumption of 
the product among the target 
audience? 
very small, just formed rapidly increasing every year 
almost all the consumers enjoys 
the product or service 
enjoyed by all, or 
there is a decline of 
interest in the cate-
gory 
0 0 1 0 
4 
How would you assess the 
level of competition in the 
market 
low: 1-3 players, practically 
do not compete with each 
other 
growing: the number of com-
petitors is growing, competi-
tive market environment is 
constantly changing 
settled:  the number of players 
practically not growing, competi-
tive market map is formed and 
virtually unchanged 
the number of play-
ers do not grow and 
even decreases 
0 1 0 0 
5 
The level of investment in the 
market increases or 
decreasing? 
growing rapidly moderate growth constant decreases 
0 1 0 0 
6 
How would you assess the 
level of prices market? 
increased, companies receive 
excess profits 
reduced due to new entrants, 
the threat of price wars 
The price level is formed and 
practically does not change. Each 
competitor takes a stable price 
niche 
stable or declining 
0 1 0 0 
TOTAL  5 1  
 APPENDIX 6/2 
  
 
№ Question 
Competitive position 
Dominant Strong Favorable Tenable Weak 
ASSESSMENT OF COMPETITIVENESS 
1 
How would you assess 
the dynamics of sales of 
the product on the mar-
ket? 
The leader in terms 
of sales. The growth 
rate of the lowest to 
the highest, but sta-
ble. 
The sales volume good and 
stable (product among the 
top three market leaders). 
The rate of growth than or 
equal to or above the market 
The sales volume good and sta-
ble, but the product is not the 
market leader. Perhaps leadership 
in specific market niches. 
Growth rates either equal or 
higher than the market. 
The sales volume is low. 
Constant fluctuations in 
the level of sales (except 
for seasonal fluctuations). 
The sales volume 
is low. The 
downward trend 
in sales. 
0 0 1 0 0 
2 
How would you assess 
the competitive ad-
vantage of your product? 
The product is 
unique in the indus-
try. 
The product has high con-
sumer qualities. it has its 
own unique properties, 
which are valued audience. 
There is competitive advantage, 
but it is also necessary to 
strengthen and bring it to the 
target audience. 
Competitive advantage is 
easy to copy. In the case 
of the arrival of a strong 
player in the industry - the 
loss of sales. 
No competitive 
advantages.  
0 1 0 0 0 
3 
How would you assess 
the level of loyalty of 
your customers and the 
ability to switch to their 
competitors' products? 
The high proportion 
of loyal customers. 
Nobody refuses a 
product or service. 
The high proportion of loyal 
customers. Minimal risk of 
switching to competitors, 
even in the face of declining 
prices. 
Loyalty to a certain extent due to 
the price level. By reducing the 
price the market is the threat of 
withdrawal of consumers to 
competitors. 
Loyalty is missing. Cus-
tomers can at any time go 
to competitors. 
Loyalty is low 
and steadily de-
clining. 
Customers leave. 
0 0 1 0 0 
4 
How would you assess 
the level of knowledge 
among the audience of 
your product? 
The most famous 
product on the 
market. 
The product is in the top 
ranking of the most famous 
players in the market. 
The average level of knowledge. 
Not included in the top, but not 
an outsider. 
The low level of 
knowledge. 
Product 
knowledge is 
almost absent. 
  1   
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* Prices of medicines are regulated and controlled by the state. 
 
№ Question 
Competitive position  
Dominant Strong Favorable Tenable Weak 
5 
How would you assess the 
level of freedom in setting 
prices for the product?* 
Our company dic-
tates the price for 
the entire market. 
We do not feel the 
restrictions of com-
petition in setting 
prices. 
Guided by the average level 
of prices in the market, but 
have the ability to set prices 
above the market average. 
The freedom in setting pric-
es only for certain groups of 
consumers who know and 
appreciate the company's 
product. For the rest of the 
market is difficult to justify 
higher prices. 
Practically there is no 
freedom in setting 
prices. Prices are 
close to average. 
Prices are dictat-
ed by the market. 
There is no pos-
sibility of price 
increases. 
0 0 0 0 1 
6 
How would you assess the 
level of threat from com-
petitors? 
The threat is absent. 
No strong competi-
tors. 
The low level of threat. 
The average level of threat. 
High competition for the 
customer. 
The high level of 
threat. At any time, 
competitors can take 
away market share. 
Competitors cap-
ture our market 
share. 
0 0 1 0 0 
TOTAL 0 1 4 0 1 
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Appendix 7. Analysis of the second level product by the I. Ansoff matrix.  
Step 1: Consider the growth opportunities in the current market with the current item. 
The strategy of penetration 
Q: Are there opportunities and growth pro-
spects in the current market for the compa-
ny? 
Possible Likely Impossible 
Describe the current market and the current 
product 
Current market: Cardio 
Current commodity: medicinal agent for nor-
malizing blood cholesterol (Statins) 
Market growth rate High 
Slow down, 
but growing 
The stagna-
tion or de-
crease in vol-
ume market. 
The level of consumption of goods among the 
target audience 
Lower than 
average 
At the level 
of the average 
indicators 
Higher than 
average 
The frequency of product use Maximum Moderate Low 
The level of goods distribution on the market (or 
access to the product) 
Lower than 
average 
At the level 
of the average 
indicators 
Higher than 
average 
Brand awareness 
Lower than 
average 
At the level 
of the average 
indicators 
Higher than 
average 
Economies of scale Yes  No 
Goods of the company has a competitive ad-
vantage in the current market (compared to 
competitors products) 
Yes  No 
Opportunities to high level of investments Yes  No 
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Step 2: Considering expanding the current product to new markets. 
Market development strategy 
Q: Will the company enter with the cur-
rent product into new markets? 
Possible Likely 
Impossi-
ble 
Describe the new market and the current product 
New market: wholesale and retail trade in new 
regions of the Russian Federation. 
Current commodity: medicinal agent for 
normalizing blood cholesterol (Statins) 
The company is successful in current activity 
(product of the company is in demand in the cur-
rent market or high loyalty to it) 
Yes 
There are mi-
nor shortcom-
ings 
No, it is 
necessary 
to improve 
the prod-
uct 
Number of players in the new market 
Small amount 
of  players (1-
3) 
The average 
level of mar-
ket saturation 
(3-10) 
The high 
level of 
market 
saturation 
Barriers to entry in a new market Almost absent 
Yes, but not 
high enough 
The high 
level of 
entry bar-
riers 
The growth rate of a new market High 
Slow down, 
but growing 
The stag-
nation or 
decrease in 
volume 
market 
This product has unique properties, has a competi-
tive advantage (in comparison with the major play-
ers in the market), or company owns a unique 
technology, or the company has a unique profita-
ble business model. 
Yes   No 
The company has additional capital for investment 
in the development of new markets. 
Yes   No 
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Step 3: Consider the possibility of creating a new product in the current market 
Product Development Strategy 
Q: Will the company successfully expand the 
range of products in the current market? 
Possible Likely Impossible 
Describe the current market and new 
product 
Current market: Cardio 
New product: extension of product "Statins" due to 
the new INN (Atorvastatin and Rosuvastatin) 
The growth rate of the current market High 
Slow down, but 
growing 
The stagna-
tion or de-
crease in vol-
ume market. 
The size of the current market (for the 
company's business) 
Large Medium  Small 
Current product is obsolete, has flaws or 
is in the final stage of the product life 
cycle 
Yes 
There is a ten-
dency to reduce 
the demand for 
current product 
No 
Intersectoral competition High 
The tendency to 
tightening 
Low 
The threat of entry of new players Yes   No 
The success of the industry depends on 
innovation and continuous offer of new 
products 
Yes   No 
Update level of assortment and the emer-
gence of new products from key competi-
tors 
High Medium Low 
Step 4: Consider the possibility of creating a new product in new markets 
Diversification strategy 
Q: Is there a need to diversify the company's 
portfolio? 
Possible Likely Impossible 
Describe the new market and new product 
New market: wholesale and retail trade in new re-
gions of the Russia, the new joint program specifica-
tions, the product of different pharmacological 
groups (Ursodez® + "Statins") 
New product: extension of product "Statins"due to 
the new INN Atorvastatin and Rosuvastatin 
The growth rate the company's current 
markets 
The stagnation 
or decrease of 
market volume 
Slow down, but 
growing 
High 
The competition in the current market High 
The tendency to 
tightening 
Low 
The company has additional resources for 
business development in the new market 
Yes   No 
The company has a certain level of com-
petence (or can achieve it) to do business 
in a new market 
Yes   No 
Growth opportunities in the current mar-
ket, and with the help of current products 
Minimal or ab-
sent 
  Yes 
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Step 5: Consider the analysis results in a free form and develop directions of works 
Strategy Possibility Description 
KEY SOURCES OF 
GROWTH 
Penetration Likely 
The company has the resources to im-
plement the strategy. It is necessary to 
stimulate progress. Expand the contract 
with distributors and marketing contract 
with the pharmacy chains. Maintain the 
competitiveness of the product. Sell 
more products to more customers. 
 Extend the 
product "Statins; 
 Stimulate pro-
motion (to pro-
vide training to 
physicians and 
pharmacists, par-
ticipation in ex-
hibitions, etc.); 
 Using brands 
and umbrella 
brands as a pro-
motion; 
 Programs of 
combined pre-
scription of 
medications 
from different 
pharmacological 
groups ( For ex-
ample Ursodez® 
+ "Statins"); 
 Geographical 
development 
and expansion of 
the wholesale 
and retail net-
works; 
Market  
development 
Impossible 
Despite the fact that the company has 
sufficient resources to implement the 
strategy, it is not recommended to 
choose. The volume of production is 
small compared to the leaders, and there 
is a risk not to take market share. Sales 
can only grow at the expense of geo-
graphical development (wholesale and 
retail sales in new regions of Russia). 
Increase the share of wholesale and re-
tail networks in existing areas. 
Product 
 development 
Possible 
The company has the resources to im-
plement the strategy. The risks are min-
imal. There are growth opportunities in 
the current market with the help of cur-
rent and new products. It is recom-
mended to extend the product "Statins” 
by the new INN Atorvastatin and 
Rosuvastatin. It is recommended to 
brand old products. 
Diversification Likely 
The company has the resources to im-
plement the strategy. High risks. 
There are growth opportunities in the 
current market with the help of current 
and new products. It is recommended 
to extend the product "Statins”. 
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Appendix 8. Neuro-SZ products allocation. 
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Appendix 9. Gastro-SZ products allocation. 
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Appendix 10. ONCO+ products allocation. 
 
 
APPENDIX 11/1 
  
Appendix 11. Potency products allocation. 
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Appendix 12. Allergy products allocation. 
 
 
APPENDIX 13/1 
  
Appendix 13. Assessment of economic efficiency of implementation of the product 
portfolio management model. 
Characteristics of the investment project. 
The project is in optimizing the product portfolio of the enterprise and in changing the 
products promotion technology. A more progressive promotion technology is proposed. 
The project is attributed to the category of projects "for changing" with maintaining of the 
production capacity. Efficiency calculation is performed on the basis of the accrual 
approach. The source (background) variant is keeping production and promotion programs 
unchanged, without implementation of the project. The main variant is a new program for 
promotion in the course of project implementation. Efficiency is revealed with comparison 
of indicators with the main and the source (background) variant. The project does not 
provide changes in production and auxiliary facilities, production capacity and equipment 
stock. 
The number of factory personnel will not be changed during implementation of the project. 
Development of pharmaceutical compositions, production technologies, and working with 
experimental production batches will be performed by existing staff by making changes to 
the production plan. The manufacturing facility works in 2 shifts, the sales office works 
from 9 a.m. to 6 p.m.  
The term of implementation of the project is 4 years, which approximately complies with 
the statutory term of repayment of products in the pharmaceutical industry. A calculation 
step is equal to 1 year. Approximate project implementation calendar schedule: 
 Year 0: accumulation of funds for the project, market monitoring, enterprise product 
portfolio analysis, development of the action plan for improvement of the product 
portfolio (2014). 
 Year 1: performance of marketing studies regarding markets of selected directions 
(products), development of pharmaceutical compositions and manufacturing tech-
nologies for the selected products, procurement of missing equipment, and working 
with experimental and production batches of products, performance of the required 
studies, registration with the Ministry of Health, launching of new SKUs to the mar-
ket, taking measures for promotion and attraction of new customers (2015). The 
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plant use factor for the 1st year is 0.85 (85%). For the 2nd and subsequent years, the 
plant use factor will be 1.0 (100%) per year. 
 Year 2: continuation of the required studies of products, registration with the Minis-
try of Health of the Russian Federation and the CIS, launching of modified products 
to the market of the Russian Federation and launching of "old" products to new CIS 
markets, taking measures for promotion and attraction of new customers (2016).  
 Year 3: continuation of registration of new products with the Ministry of Health, 
launching of new products to the market, taking measures for promotion and attrac-
tion of new customers, analysis of the product portfolio, and development of correc-
tion measures (2017). 
 Year 4: taking measures for promotion and attraction of new customers, marketing 
research, analysis of the product portfolio, and determination of new products 
(2018). 
The discount rate is calculated with a cumulative method, according to which the discount 
rate is the sum of the risk-free (basic) rates and surcharges (premium) for risk 
r=rбр + rр , 
where rбр is the risk-free (basic) rate; 
rр is the premium for the risk. 
The risk-free interest rate should be refinancing rate of the Central Bank of the Russian 
Federation, which is 8% p.a. The premium for the risk is assumed as 3%. 
r=8 + 3 = 11%, 
The project is attributed to medium risk projects as most of measures proposed by the 
author provide for output of well-known products under known or new technologies with 
existing production facilities. The actual discount rate is selected as 11%. It is planned to 
fund the project with equity funds of the enterprise. 
The following are calculations of profit and loss indicators.  
Calculation of capital-forming investments is set forth in Table 1.  
APPENDIX 13/3 
  
Table 1. Calculation of capital-forming investments 
Investment  
Costs 
Calculation procedure Amoun
t, 
thousa
nds 
rub.  
New equipment acquired Cost of new equipment plus installation cost 
(20%) 
1000 
Used equipment available at the en-
terprise to be applied for the project 
Cost of the available equipment at the residual 
balance cost (the wear is 40%) 
12446 
Non-capitalized expenses Marketing study  
Development of pharmacological composition  
Clinical and additional studies  
State registration  
Patent expenses 
Research and development 
30130 
Total investment costs 44576 
Exclusive of the cost of used equipment 31130 
Initial cost of the new equipment 
acquired (excl. of VAT) 
Cost of new equipment indicated in clause 1 and 
divided by 1.18. 
800 
Initial cost of the used equipment 
(excl. of VAT) 
Residual cost of clause 2 divided by the wear fac-
tor  
8890 
Comparison of the source and the basic variant were revealed factors of changes, economic 
consequences and changing items of operational costs. (See Table 2) 
Table 2. An analysis of the changes and their economic consequences 
Factor of changes Economic Implications The amended article costs 
Implementation of the 
modified drug, SKU op-
timization 
Lower costs for raw materials. 
Reduced power consumption. 
Basic materials 
Electric energy 
Retrofitting park equip-
ment, purchase of addi-
tional equipment 
Due to the increase in the cost of 
park equipment: 
Increases the cost of maintenance 
and repair of equipment 
Increased amortization of  equipment 
 
Maintenance and repair of 
equipment 
 
Amortization 
On the basis of the data in Table 1, calculation of changing operation costs on the source 
and the basic variant has been performed. It results are summarized in Table 3. 
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Table 3. Calculation of change (savings or gains) in operating costs for the project imple-
mentation 
Article ex-
penses 
The original version The basic version Saving 
"+" gain 
"-" Amount, 
thousand 
rub.. 
Note Amount, 
thousand 
rub.. 
Note 
1 2 3 4 5 6 
Variable expenses for year 
Basic materials 452114 According to 
the company’s’ 
data 
427676 Decrease con-
sumption rates by 
5% 
24469 
Energy 3199 Same 2996 Decrease con-
sumption rates by 
7% 
203 
Total variable cost savings of making full use of the equipment ( for 2nd and subse-
quent years) 
24672 
 
Total variable cost savings in the utilization rate of equipment 0.85 (1st year) Calcula-
tion: 24672 * 0.85 
20971,2 
Fixed costs for the year 
Maintenance 
and repair 
249 2% of the total 
cost 
259 2% of the total 
cost 
-10 
Итого прирост постоянных затрат (без амортизации) за год 10 
Equipment 
amortization 
1245 10% of the total 
cost of the 
equipment 
1249 10% of the total 
cost of the 
equipment 
-4 
Note. Cost savings is taken into account as part of further inflows. Gain costs are taken into account 
as part of outflows from operating activities. 
Calculation of Economic Efficiency Indicators 
As the project is funded with equity funds of the enterprise, monetary flows (differences 
between inflows and outflows) have been determined only for operational and investment 
activities. Calculation of economic efficiency indicators is performed in Table 4. 
The following are explanations of the calculation. 
Operational cash inflows (cl.1) comprise of economy of temporary costs taken from Table 
3. Operational cash outflows (cl.3) are taken from Table 3 in accordance with continuous 
costs articles (excl.  of depreciation), where growth is observed. Depreciation of new 
equipment (cl.4) is determined on the basis of the initial cost (excl. of VAT) of the 
equipment acquired (see cl.4 of Table 3) with the depreciation rate of 10%. This article is for 
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reference only and is not used in the course of calculation of the resultant cash flows. It is 
only used for calculation of growth of the income tax. 
Growth of the income tax (cl.5) is calculated on the basis of the fact the total decreasing of 
operational costs is equal to the growth of profits from sales.  With the rate of 20% of 
profits (or, correspondingly, from the total decreasing of operational costs), it is calculated as 
follows: (cl.2 – cl.3 – cl.4)*0.2. If the profit growth is negative, the income tax growth is 
equal to zero. The property tax growth (cl.6) is calculated at the rate of 2.2 percent of the 
average annual cost of the acquired fixed assets (excl. of VAT) with the following formula: 
Hимt = Sпол * [1 – Hам *(t-0.5)]*0,022, 
where 0.022 is the property tax rate; 
Sпол is the full initial cost (excl. of VAT) of the acquired fixed assets (new equipment), see 
Table 1, cl.5; 
Hам is the average annual depreciation rate for the acquired equipment, in our example: 0.1 
(10%); 
t is the ordinal number of year (calculation step). 
Total operational outflow (cl.7) is the sum of cl.3, cl.5, and cl.6. Operational cash flow (cl.8) 
is the difference between inflows and outflows (cl.2 to cl.7). Capital-forming investments 
(cl.9): see Table 1. Investment activities cash flow (cl.11) is the difference between inflows 
and outflows (cl.10 to cl.11). Total cash flow (Cl.15) is the sum of cash flows in operational, 
investment, and financial activities (cl.9 + cl.11 + cl.14). Discount rate (cl.16) is determined 
by the formula of the fourth function of the monetary unit: Кdisc=1/(1+r)
t, where r is the 
discount rate (0,11); t is the ordinal number of year. Total cash discount rate (cl.17) is the 
product: cl.15 * cl.16. Operational activities cash discount flow (cl.19) is the product of cl.8 * 
cl.16. Investment activities cash discount flow (cl.19) is the product of cl.11 * cl.16. Growth 
of net present value on the project (cl.21) is the sum under cl.17 or the last number of cl.18. 
The discounted transactions profitability index (cl.22) is the ratio of the amount of 
operational discounted cash flow to the absolute value of the cash flow under investment 
activities: amount under cl.19 / |amount under cl.20|. Discounted payback period (cl.23) is 
the moment of time after commencement of the project when accumulated total discounted 
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cash flow changes its value from negative to positive (see cl.18). It is determined by the 
following formula: 
, 
where t is the last year in which the accumulated total discounted cash flow under the 
project was negative (in this example, t = 2); 
|ДДПнакt| is the absolute value of accumulated total discounted cash flow in year t, in our 
case, | -5,975| thousand rub., see cl.19; 
ДДПt+1 is discounted cash flow in year t + 1, in our case, 20,182 thousand rub., see cl.18 
Ток = 2 + (5,975/20,182) = 2.3 years or 2 years and 3 months. 
 
1tДДП
накtДДП
tокТ


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Table 4. Calculation of economic (commercial efficiency of the project) 
Indicators by years: 0 1 2 3 4 
1 2 3 4 5 6 
The utilization of equipment   0,85 1 1 1 
OPERATING ACTIVITIES 
Cash inflows 
1) Variable cost savings  0 20971 24672 24672 24672 
2) Total inflows from operating activities  0 20971 24672 24672 24672 
Cash outflows          
3) The growth of fixed costs 0 10 10 10 10 
4) Reference: depreciation of fixed assets thousand rub. 0 4 4 4 4 
5) The growth of income tax 0 4191,4 4931,6 4931,6 4931,6 
6) The growth of  property tax 0 17 15 13 11 
7) Total cash outflows from operating activities 0 9183 14875,8 9915,2 4956,6 
8) Cash flow from operating activities 0 11788 9796,2 14756,8 19715,4 
INVESTMENT ACTIVITIES 
Cash inflows           
9) The market value of released equipment  0 0 0 0 0 
Cash outflows           
10) Capital forming investments (without the cost of used equipment) 31130 0 0 0 0 
11) Cash flow from investing activities -31130 0 0 0 0 
FINANCING ACTIVITIES 
Cash inflows           
12) Total cash inflows from financing activities 0 0 0 0 0 
Cash outflows           
13) Total cash outflows from financing activities 0 0 0 0 0 
14) Cash flow from financing activities 0 0 0 0 0 
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Indicators by years: 0 1 2 3 4 
1 2 3 4 5 6 
      
15) Total cash flow for the project -31130 11788 9796,2 14756,8 19715,4 
16) The discounting factor (at a discount rate of 11%) 1 0,9009 0,8116 0,7312 0,6579 
17) The total discounted cash flow for the project -31130 13085 12070 20182 29967 
18) Accumulated result   -18045 -5975 14207 44174 
19) Discounted cash flow from operating activities 0 13085 12070 20182 29967 
20) Discounted cash flow from investing activities 31130 0 0 0 0 
INDICATORS OF PROJECT EFFECTIVENESS 
21) NPV increase in the project 44174     
22) Profitability index of discounted investment 2     
23) Discounted payback period, years 2,3     
24) Internal rate of return (IRR) 18%     
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Internal rate of return (IRR; see cl.24) is the value of the discount rate with which the NPV 
of the project turns to zero with other equal conditions. It is determined with the IRR 
function in MS EXCEL with the input from the line of accumulated cash flow on the 
project (cl.15).  
IRR can be approximately determined by building a graph that shows dependency of the 
project NPV on the r discount rate. The NPV line = f(r) crosses the zero point only once. 
To the left, near the zero point, point 1 is found on the line with the following coordinates: 
+NPV1, r1. To the right, near the zero point, point 2 is found on the line with the following 
coordinates: -NPV2, r2. The points are connected with a straight line and the point of 
crossing of the line with the horizontal axis is found, which indicates the IRR value. 
 
APPENDIX 14/1 
  
Appendix 14. Activities to improve the product portfolio of ZAO «Severnaya Zvezda».  
Activities Development of a new INN product  Modification of the INN product  NEW SKU 
Geographic expansion: 
Medicines for countries 
of the CIS 
Transfer of 
production 
rights 
Research 1. Market research 
300 000 
rub./1 
month 
1. Market research 
100 000 
rub./ 
1 month 
Demand is detect-
ed during sales 
1. Market research 
200 000 rub./ 1 month 
No 
Production 
2.1. Development of 
pharmaceutical composi-
tions and production 
technology, 
2.2. Purchase of missing 
equipment 
2.3. Production of trial 
batch 
2.4. Establishment of in-
dustrial regulations 
1500 
thous. rub. 
/4 months 
 
2.1. Development of 
pharmaceutical composi-
tions and production 
technology, 
2.2. Purchase of missing 
equipment 
2.3. Production of trial 
batch 
2.4. Establishment of in-
dustrial regulations 
500 thous. 
rub. / 
2 months 
 
100 thous. rub. / 
2 months 
 
2.1. Production of trial 
batch 
2.2. Establishment of in-
dustrial regulations 
 
100 thous. rub. / 
2 months 
 
No 
Clinical studies 
Preclinical, clinical and 
other studies 
4900 
thous. rub. 
/ 
12 months 
Additional studies 
675 thous. 
rub./ 
4 months 
No If required No 
Registration in 
the Ministry of 
Health 
Yes 
300 thous. 
rub. / 
16  months 
 
Yes 
225 thous. 
rub. / 
10 months 
Yes 
Yes 
 200-300 thous. rub. / 10 
months 
Yes 
150 thous. 
rub. 
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Activities Development of a new INN product  Modification of the INN product  NEW SKU 
Geographic expansion: 
Medicines for countries 
of the CIS 
Transfer of 
production 
rights 
Market launch Yes 
1 000 
thous. rub. 
/3 months 
 
Yes 
500 thous. 
rub. /3 
months 
Yes 
Yes 
500 thous. rub. /5 
months 
Yes 
Market share From  0,1 to 3 % 12 months 
Growth up to 5% to the 
existing share 
4 months 
Market share 
maintained or in-
creased during 1-2 
months 
Capturing market share 
during 12 months 
No 
Increasing 
margins 
Due to the development 
of new market and in-
crease prices 
8 000 
thous. rub. 
/48 
months 
Due to increase market 
share, prices and cost re-
duction 
2000 
thous. rub. 
/ 24 
months 
Due to the market 
share  increase, 
creation of micro-
niches, reducing 
costs 
 
(100 thous. rub. / 
3 months.) 
Due to the market share  
increase, the establish-
ment of new niches, re-
ducing costs, increasing 
prices 
 
(1500 thous. rub. 
/30 months) 
5 - 7%  
royalty on 
sales 
 
 
